

► OphthalmologyTimes.com

FOLLOW US ONLINE: [f](#) [t](#)

Drug Therapy


COMBINED THERAPY SHOWS PROMISE FOR DME PATIENTS

INDIANAPOLIS :: **ANTI-VASCULAR** endothelial growth factor agents alone may not provide the optimal response for all patients with diabetic macular edema, said Raj K. Maturi, MD, private practice, Midwest Eye Institute, and Department of Ophthalmology, Indiana University School of Medicine, Indianapolis.

(See story on page 26 : DME)

Special Report

NEW TECHNOLOGY ENTERING NEW ERA OF DRY EYE CARE



NEW YORK :: **RECENT TECHNOLOGICAL** advances are improving the diagnosis of dry eye disease and should enable more timely intervention that will help to reduce the morbidity of this common condition, according to Christopher E. Starr, MD, associate professor of ophthalmology, Weill Cornell Medical College, New York.

(See story on page 11 : Technology)

Sjögren's syndrome on the radar

How underdiagnosis of disorder can lead to significant morbidity, and even mortality

By Cheryl Guttman Krader;

Reviewed by Esen Akpek, MD

BALTIMORE ::


OPHTHALMOLOGISTS WHO SEE patients with dry eye must maintain an index of suspicion for Sjögren's syndrome so that affected individuals are properly diagnosed and treated, said Esen Akpek, MD.

"Sjögren's syndrome is most often associated with dry eye and dry mouth," said Dr. Akpek, professor of ophthalmology and rheumatology; director, Ocular Surface Disease and Dry Eye Clinic, and associate director, Johns Hopkins Jerome L. Greene Sjögren's Syndrome Center, Wilmer Eye Institute at Johns Hopkins University School of Medicine, Baltimore.

"While those features are its most common early manifestations, Sjögren's syndrome is a multisystem autoimmune disease that can result in significant morbidity from joint and internal organ involvement as well as mortality through its association with lymphoma," Dr. Akpek said.

Early recognition and treatment are important for minimizing disease progression, Dr. Akpek noted. Unfortunately, although Sjögren's syndrome is one of the most common autoimmune diseases, it is also one of the most underdiagnosed.

EFFECT OF CONDITION ON PATIENT EYE



► **Slit lamp examination of a paracentral sterile corneal necrosis in a patient with Sjögren's syndrome and associated dry eye.**

► **In addition, the presence of dry mouth or other systemic complaints associated with other tissue damage from Sjögren's syndrome may be a useful predictor.** (Image courtesy of Esen Akpek, MD)

Lack of suspicion for Sjögren's syndrome—fueled by underappreciation of its true prevalence—is one reason why the disease is underdiagnosed or not diagnosed before the development of permanent tissue damage, Dr. Akpek said.

Affected patients often present to a primary eye-care provider because of their dry eye and do not receive the evaluation that would lead to a proper diagnosis.

"It is the responsibility of ophthalmologists and optometrists who see patients with dry eye complaints to raise the suspicion of Sjögren's syndrome and begin the work-up just as it would be done if the patient presented with uveitis," Dr. Akpek said. "Dry eye is


(Continues on page 15 : Sjögren's syndrome)

Today, she presents
with dry eye symptoms.



nicox 
Ophthalmic Diagnostics

Sjögren's
SS syndrome
F foundation



What will she look like by
the time she is diagnosed?

For millions of dry eye patients,
their symptoms could be an early sign
of a progressive autoimmune disease.^{1,2}

As many as 1 in 10 patients with dry eye also have Sjögren's
Syndrome, a chronic condition of deteriorating exocrine
glands that can have significant systemic ramifications.²⁻⁴

Today, it takes an average of 4.7 years to receive an
accurate diagnosis.² Together with the Sjögren's
Syndrome Foundation, Nicox is out to change that.

Join us in the fight at **morethandryeye.com**, or
call **1.855.MY.NICOX** (1.855.696.4269) to learn more.

References: 1. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. *Arch Intern Med.* 2004;164:1275-1284. 2. Sjögren's Syndrome Foundation. Sjögren's Syndrome Foundation. 2001. Available at <http://www.sjogrens.org>. Accessed September 5, 2013. 3. Liew M, Zhang M, Kim E, et al. Prevalence and predictors of Sjögren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. *Br J Ophthalmol.* 2012;96:1498-1503. 4. Martin LS, Massafra U, Migliore A. Sjögren's syndrome: an under-diagnosed disorder. *CLJ.* May 2004.

Living in a bacterial world

Might malicious microbes make a mockery of modern medicine?



By Peter J. McDonnell, MD

director of the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, and chief medical editor of *Ophthalmology Times*.

He can be reached at 727 Maumenee Building
600 N. Wolfe St. Baltimore, MD 21287-9278
Phone: 443/287-1511 Fax: 443/287-1514
E-mail: pmcdonn1@jhmi.edu

WHEN HALLOWEEN COMES

EACH year the television networks advertise their many scary movie marathons. In these cinematographic masterpieces, shapely young women decide to walk around by themselves in the dark only to be attacked by chainsaw-wielding maniacs or crazy men wearing hockey masks.

Although I am personally not enamored of these films, they must meet an important need of my countrymen, considering that Hollywood spits out sequel after sequel.

A related genre of film is that in which the people are attacked by some natural predator, such as great white sharks in the Atlantic Ocean (*Jaws*) or giant snakes in the Amazon River of Brazil (*Anaconda*).

When I do watch these movies, having a pretty good idea that one or more of the protagonists is going to have something bad happen, the anticipation of the scary part results in a lot of boredom as the initial character development takes place. Is the giant man-eating snake about to leap out of the water and grab Ice Cube and JLo, or do I have to wait before the screams and excitement begin? Is that knocking at the door simply the local farmer, or is it the deranged mass-murderer?

ENTER DEADLY SUPER-BACTERIA

Well, that is how I am starting to feel about the long-heralded arrival of all the deadly super-bacteria. I believe you know about these, as they are routinely given front-page attention on our newspapers and prominent coverage in television news. These are the germs that can't be stopped, we are told, because they have developed resistance to all the antibiotics at our disposal.

It's just a matter of time, we have been told for at least a decade, before these malicious microbes make a mockery of modern medicine.

According to the CDC, 2 million Americans now suffer infections each year from these bacteria, and 23,000 of us die.

There have always been infections that are difficult to treat (e.g., acanthamoeba or fungal keratitis), but that was no less the case 20 years ago than it is today. Bacterial infections are not (in my humble opinion) particularly more a concern today than they were a decade or two ago.

In a recent poll of *Ophthalmology Times* readers, we asked whether drug-resistant bacterial infections were a concern in their practices.

- Fifty-nine percent of respondents described these "superbugs" as "not an issue."
- Eighteen percent reported them to be of minimal concern.
- Only 23% reported that they had experienced a significant encounter or encounters with the dread antibiotic-resistant organisms.

So, roughly 4 in 5 ophthalmologists are like the movie-goer with the tub of popcorn on his or her lap, waiting for the ax-wielding miscreant who never seems to make an appearance.

Why the disconnect between the ominous warnings of these monstrous microorganisms and the experience of most ophthalmologists?

Is it the case that these malignant microbes simply fall victim to the very high levels of antibiotics we ophthalmologists can deliver topically to the cornea with our drops or intravitreally with our injections—even if they measure as being resistant in the lab when tested against the very low antibiotic concentrations achievable in the bloodstream?

Or, are we like the teenager in the movie who, lulled into a false sense of security, decides to go for a moonlight swim, unaware of the fin breaking the water's surface yards behind us? ■

References

- http://www.nytimes.com/2013/09/17/health/cdc-report-finds-23000-deaths-a-year-from-antibiotic-resistant-infections.html?_r=0
- <http://download-latest-movie.blogspot.com/2012/09/anaconda-1997-720p-bluray-500mb-mkv.html>

Ophthalmology Times

NOVEMBER 15, 2013 ■ VOL. 38, NO. 22

CONTENT

Chief Medical Editor Peter J. McDonnell, MD
Group Content Director Mark L. Dlugoss
mdlugoss@advanstar.com 440/891-2703
Content Channel Director Sheryl Stevenson
sstevenson@advanstar.com 440/891-2625
Content Specialist Rose Schneider
rschneider@advanstar.com 440/891-2707
Group Art Director Robert McGarr
Art Director Nicole Davis-Slocum
Anterior Segment Techniques Ernest W. Kornmehl, MD
Cataract Corner Richard S. Hoffman, MD and Mark Packer, MD
coding.doc L. Neal Freeman, MD, MBA
Money Matters John J. Grande, Traudy F. Grande, and John S. Grande, CFPs®
Neuro-Ophthalmology Andrew G. Lee, MD
Ophthalmic Heritage Norman B. Medow, MD
Panretinal View Allen C. Ho, MD
Plastics Pearls Richard Anderson, MD
Tech Talk H. Jay Wisnicki, MD
Uveitis Update Emmett T. Cunningham Jr., MD, PhD, MPH
What's New at the AAO John Gallagher

PUBLISHING/ADVERTISING

Executive Vice President Georgiann DeCenzo
gdecenzo@advanstar.com 440/891-2778
VP, Group Publisher Ken Sylvia
ksylvia@advanstar.com 732/346-3017
Group Publisher Leonardo Avila
lavila@advanstar.com 302/239-5665
Associate Publisher Erin Schluskel
eschluskel@advanstar.com 215/886-3804
National Account Manager Rebecca A. Hussain
rhussain@advanstar.com 415/932-6332
Vice President Healthcare Technology Sales Drew DeSarle
ddesarle@advanstar.com 440/826-2848
Account Manager, Classified/Display Advertising Darlene Balzano
dbalzano@advanstar.com 440/891-2779
Account Manager, Recruitment Advertising Jacqueline Moran
jmoran@advanstar.com 440/891-2762
Business Director, eMedia Don Berman
dberman@advanstar.com 212/951-6745
Director, Sales Data Gail Kaye
Sales Support Hannah Curtis
Reprints 877-652-5295 ext. 121 / bkolb@wrightsmedia.com
Outside US, UK, direct dial: 281-419-5725. Ext. 121
List Account Executive Renée Schuster
rschuster@advanstar.com 440/891-2613
Permissions/International Licensing Maureen Cannon
mcannon@advanstar.com 440/891-2742

PRODUCTION

Senior Production Manager Karen Lenzen

AUDIENCE DEVELOPMENT

Corporate Director Joy Puzzo
Director Christine Shappell
Manager Wendy Bong

ADVANSTAR

Chief Executive Officer: Joe Loggia
Chief Executive Officer Fashion Group,
Executive Vice-President: Tom Florio
Executive Vice-President, Chief Administrative Officer & Chief Financial Officer: Tom Ehardt
Executive Vice-President: Georgiann DeCenzo
Executive Vice-President: Chris DeMoulin
Executive Vice-President: Ron Wall
Executive Vice-President, Business Systems: Rebecca Evangelou
Executive Vice-President, Human Resources: Julie Mollleston
Sr Vice-President: Tracy Harris
Vice-President, Information Technology: Joel Horner
Vice-President, Legal: Michael Bernstein
Vice-President, Media Operations: Francis Heid
Vice-President, Treasurer & Controller: Adele Hartwick

Advanstar Communications Inc. provides certain customer contact data (such as customers' names, addresses, phone numbers, and e-mail addresses) to third parties who wish to promote relevant products, services, and other opportunities that may be of interest to you. If you do not want Advanstar Communications Inc. to make your contact information available to third parties for marketing purposes, simply call toll-free 866-529-2922 between the hours of 7:30 a.m. and 5 p.m. CST and a customer service representative will assist you in removing your name from Advanstar's lists. Outside the U.S., please phone 218-740-6477.

Ophthalmology Times does not verify any claims or other information appearing in any of the advertisements contained in the publication, and cannot take responsibility for any losses or other damages incurred by readers in reliance of such content.

Ophthalmology Times cannot be held responsible for the safekeeping or return of unsolicited articles, manuscripts, photographs, illustrations or other materials.

Ophthalmology Times is a member of the Association of Independent Clinical Publications Inc.

Library Access Libraries offer online access to current and back issues of *Ophthalmology Times* through the EBSCO host databases.

To subscribe, call toll-free 888-527-7008. Outside the U.S. call 218-740-6477.



Official publication sponsor of



Ophthalmology Times EDITORIAL ADVISORY BOARD

Chief Medical Editor

Peter J. McDonnell, MD
Wilmer Eye Institute
Johns Hopkins University
Baltimore, MD

Associate Medical Editors

Dimitri Azar, MD
University of Illinois, Chicago
Chicago, IL

Anne L. Coleman, MD
Jules Stein Eye Institute, UCLA
Los Angeles, CA

Ernest W. Kornmehl, MD
Harvard & Tufts Universities
Boston, MA

Robert K. Maloney, MD
Los Angeles, CA

Joan Miller, MD
Massachusetts Eye & Ear Infirmary
Harvard University
Boston, MA

Randall Olson, MD
University of Utah
Salt Lake City, UT

Robert Osher, MD
University of Cincinnati
Cincinnati, OH

Ophthalmology Times Mission Statement

Ophthalmology Times is a physician-driven media brand that presents cutting-edge advancements and analysis from around the world in surgery, drug therapy, technology, and clinical diagnosis to elevate the delivery of progressive eye health from physician to patient.

Ophthalmology Times' vision is to be the leading content resource for ophthalmologists.

Through its multifaceted content channels, *Ophthalmology Times* will assist physicians with the tools and knowledge necessary to provide advanced quality patient care in the global world of medicine.

Anterior Segment/Cataract Cornea/External Disease

Ashley Behrens, MD
Wilmer Eye Institute, Johns Hopkins University
Baltimore, MD

Rubens Belfort Jr., MD
Federal University of São Paulo
São Paulo, Brazil

Elizabeth A. Davis, MD
University of Minnesota
Minneapolis, MN

Uday Devgan, MD
Jules Stein Eye Institute, UCLA
Los Angeles, CA

Richard S. Hoffman, MD
Oregon Health & Science University
Portland, OR

Samuel Masket, MD
Jules Stein Eye Institute, UCLA
Los Angeles, CA

Bartly J. Mondino, MD
Jules Stein Eye Institute, UCLA
Los Angeles, CA

Mark Packer, MD
Oregon Health & Science University
Portland, OR

Michael Raizman, MD
Massachusetts Eye & Ear, Harvard University
Boston, MA

Michael Snyder, MD
Cincinnati Eye Institute
Cincinnati, OH

Walter J. Stark, MD
Wilmer Eye Institute, Johns Hopkins University
Baltimore, MD

Farrell "Toby" Tyson, MD
Cape Coral, FL

Glaucoma

Robert D. Fechtner, MD
University of Medicine & Dentistry of New Jersey
Newark, NJ

Neeru Gupta, MD
University of Toronto
Toronto, Canada

Malik Kahook, MD
University of Colorado, Denver
Denver, CO

Richard K. Parrish II, MD
Bascom Palmer Eye Institute, University of Miami
Miami, FL

Harry A. Quigley, MD
Wilmer Eye Institute, Johns Hopkins University
Baltimore, MD

Robert Ritch, MD
New York Eye & Ear Infirmary
New York, NY

Joel Schuman, MD
University of Pittsburgh Medical Center
Pittsburgh, PA

Kuldev Singh, MD
Stanford University
Stanford, CA

Robert N. Weinreb, MD
Hamilton Glaucoma Center
University of California, San Diego

Neuro-Ophthalmology

Andrew G. Lee, MD
Methodist Hospital, Texas Medical Center
Houston, TX

Oculoplastics/Reconstructive Surgery

Robert Goldberg, MD
Jules Stein Eye Institute, UCLA
Los Angeles, CA

John T. LiVecchi, MD
St. Luke's Cataract & Laser Institute
Tarpon Springs, FL

Shannah L. Merbs, MD
Wilmer Eye Institute, Johns Hopkins University
Baltimore, MD

Pediatric Ophthalmology

Norman B. Medow, MD
Albert Einstein College of Medicine
Bronx, NY

Jennifer Simpson, MD
University of California, Irvine
Irvine, CA

H. Jay Wisnicki, MD
New York Eye & Ear Infirmary, Beth Israel Medical Center, Albert Einstein College of Medicine
New York, NY

Practice Management

Joseph C. Noreika, MD
Medina, OH

Frank Weinstock, MD
Boca Raton, FL

Refractive Surgery

William Culbertson, MD
Bascom Palmer Eye Institute, University of Miami
Miami, FL

Kenneth A. Greenberg, MD
Danbury Hospital
Danbury, CT
New York University
New York, NY

Peter S. Hersh, MD
University of Medicine & Dentistry of New Jersey
Newark, NJ

Jonathan H. Talamo, MD
Harvard University
Boston, MA

Kazuo Tsubota, MD
Keio University School of Medicine
Tokyo, Japan

Retina/Vitreous

Stanley Chang, MD
Columbia University
New York, NY

David Chow, MD
University of Toronto
Toronto, Canada

Pravin U. Dugel, MD
Phoenix, AZ

Sharon Fekrat, MD
Duke University
Durham, NC

Julia Haller, MD
Wills Eye Institute, Thomas Jefferson University
Philadelphia, PA

Tarek S. Hassan, MD
Oakland University
Rochester, MI

Michael Ip, MD
University of Wisconsin
Madison, WI

Carmen A. Puliafito, MD
Keck School of Medicine, USC
Los Angeles, CA

Carl D. Regillo, MD
Wills Eye Institute, Thomas Jefferson University
Philadelphia, PA

Lawrence J. Singerman, MD
Case Western Reserve University
Cleveland, OH

Uveitis

Emmett T. Cunningham Jr., MD, PhD
Stanford University
Stanford, CA

Chief Medical Editors-Emeritus

Jack M. Dodick, MD
New York University School of Medicine
New York, NY (1976-1996)

David R. Guyer, MD
New York, NY (1996-2004)

Ophthalmology Times Industry Council

John Bee
Rhein Medical Inc.
President and CEO

William Burnham, OD
Carl Zeiss Meditec Inc.
Director of Market Development, Americas

Alastair Douglas
Alcon Laboratories Inc.
Director of U.S. Commercial Support

Bob Gibson
Topcon Medical Systems Inc.
Vice President of Marketing

Marc Gleeson
Allergan Inc.
Vice President, U.S. Eye Care Pharmaceuticals
Glaucoma and External Disease Marketing

Ram Palanki
ThromboGenics Inc.
Global Head - Marketing and Sales

Daina Schmidt
Bausch + Lomb Surgical
Global Executive Director of Product Strategy

Kelly Smoyer
Essilor of America
Product Director

John Snisarenko
Genentech USA Inc.
Vice President, Sales and Marketing

Chris Thatcher
Reichert Technologies
Division Vice President and Reichert Business Unit Manager

How to Contact Ophthalmology Times

Editorial
24950 Country Club Blvd.,
Suite 200
North Olmsted, OH 44070-5351
440/243-8100
FAX: 440/756-5227

Subscription Services
Toll-Free: 888/527-7008 or
218/740-6477
FAX: 218/740-6417

Advertising
485 Route 1 South
Building F, Suite 210,
Iselin, NJ 08830-3009
732/596-0276
FAX: 732/596-0003

Production
131 W. First St.
Duluth, MN 55802-2065
800/346-0085
FAX: 218/740-7223,
218/740-6576

Dry Eye Lid Squeezers

Meibum Expression

Rollers Closed

8-01716: Maskin™ Meibum Expressor**

8-01717: Harden Eyelid Compression Forceps**

www.RheinMedical.com

Meibum Expression Is Recommended As A Subsequent Procedure To Meibomian Gland Probing, Insuring The Patency Of Meibomian Glands.

Call 800-637-4346 For More Information.




RHEIN Medical inc.

3360 Scherer Drive, Suite B, St. Petersburg, FL 33716
800-637-4346 • Tel: 727-209-2244 • Fax: 727-341-8123
Email: Info@RheinMedical.com • Website: www.RheinMedical.com
*Developed In Coordination With Steven L. Maskin, M.D., Patent Pending
** Developed In Coordination With David R. Harden, M.D.

Rhein Medical Stylized Eye

1321 Rev.B

BAB



Clinical Diagnosis

10 PATIENT SATISFACTION PLAYS ROLE IN IOL CHOICE

Each lens may be best suited to specific subset based on individual preferences, sensitivities

Drug Therapy

26 STEROIDS, ANTI-VEGFS SHOW PROMISE IN DME PATIENTS

Adding dexamethasone implant to bevacizumab results in lower subfield thickness, OCT volume

Special Report on page 11

DRY EYE

Technology

23 NEW GENERATION FOR GLISTENING-FREE IOL

Surgeon's personal experience helpful when explaining procedure to patients

Practice Management

32 MEDICARE FEE SCHEDULE: DEJA VU ALL OVER AGAIN?

Proposed 24% decrease in physician payment rates not likely if past is any indication

In Every Issue

- 4 EDITORIAL
- 8 FOCAL POINTS
- 29 MARKETPLACE

On Twitter

Recent hashtags *Ophthalmology Times* has used on twitter.com/OphthTimes

#ophthalmology #myopia
 #ARVO2013 #cataract
 #ASCRSASOA2013 #dryeye
 #eyecare #dispensing
 #astigmatism #optical
 #retina #AMD


Digital App


Introducing the *Ophthalmology Times* app for iPad and iPhone. Download it for free today at OphthalmologyTimes.com/OTapp.




Video

View a triple procedure called ICE: iStent, Cataract, and Endocyclophotocoagulation. Go to <http://bit.ly/17BH5AD>






Pre-op



Pre-op



Intra-op

Image.

Capture key diagnostic measurements, including:

- Dynamic keratometry
- Pupillometry, W2W, limbus
- Eccentricity of the visual axis

Simultaneously register the unique "fingerprint" of your patient's eye:

- Iris
- Limbus
- Scleral vessels

Plan.

Conveniently and confidently determine a surgical plan targeting your desired outcome

- Multiple advanced IOL formulas
- Plan all incisions, rhexis, and IOL alignment with precision based on the reference image
- Comprehensive astigmatism planner

Guide.

Brings your customized plan to your fingertips, at each stage in the surgical process

- Recognizes the patient, plan, and location for all key steps during surgical execution
- Communicates your pre op plan with key pieces of Cataract Refractive Surgical equipment.
- Eliminates the need for manual eye markings
- Accounts for all cyclorotation
- Documents all case metrics and data to help you analyze and optimize your procedures over time

Introducing the new VERION™ Image Guided System*:
Designed to help you consistently hit your refractive target.

*The VERION™ Image Guided System is composed of the VERION™ Reference Unit and the VERION™ Digital Marker.

Alcon
a Novartis company

© 2013 Novartis 10/13 VRN13015JAD-B

VERION
IMAGE GUIDED SYSTEM

CONTACT YOUR ALCON REPRESENTATIVE FOR MORE INFORMATION.
For important safety information, please see adjacent page.

ARVO gears up for 2014

Association's annual meeting theme promises 'Leading Eye and Vision Research'

ARVO View By Katrina Norfleet

It is not too early for the vision science community to make plans for the 2014 meeting of the Association for Research in Vision and Ophthalmology (ARVO).

As the year winds down, the association also recognizes updates and achievements in translational research and opens up nominations for the ARVO Achievement Awards.

TRANSLATIONAL RESEARCH

Translational Vision Science & Technology (TVST)—the new-

est open-access, online and peer-reviewed journal published by ARVO—features articles on multidisciplinary research that bridge the gap between basic research and clinical care.

TVST has included articles in areas of low vision, genetic and ophthalmic imaging, as well as a special issue covering nanotechnology and regenerative medicine—*Vision Restoration: Regenerative Medicine in Ophthalmology*.

To read the articles, or submit a transcript, visit the TVST website at tvstjournal.org.

CLINICIAN-SCIENTISTS AWARDED

Congratulations to the 2014 Pfizer Camras Translational Research Award recipients. These early-career researchers have exhibited excellence in research and in fundamental scientific discoveries:

■ **Rajendra Apte, MD, PhD (IM), Washington University School of Medicine:** Dr. Apte's findings spawned a series of translational studies, which led to an age-related macular degeneration (AMD) drug development initiative and biomarker development for dry eye disease and AMD.

■ **Farhad Hafezi, MD, PhD (CO), Geneva University Hospitals and University of Southern California, Los Angeles:** Dr. Hafezi was one of the core team of innovators who developed and brought to market the corneal collagen crosslinking method and transitioned this method from basic/pre-clinical studies to later arresting corneal degeneration caused by keratoconus in patients.

■ **Hendrik P.N. Scholl, MD, MA (RE), Johns Hopkins University School of Medicine:** Dr. Scholl, one of the few retinal dystrophy experts in the world who is also an accomplished vitreo-retinal surgeon, was recognized for his contributions to the understanding of the pathophysiology of blinding eye diseases.

ACHIEVEMENT AWARDS

ARVO Achievement Awards are an opportunity to recognize members of the vision research community for their exceptional contributions to ophthalmology and visual science. Awards include the Proctor Medal and the Weisenfeld, Friedenwald, and

Key dates for 2014 ARVO Meeting

NOW: Hotel reservations open
NOW: Registration open
DEC. 6: Abstract submission closes
DEC. 6: Deadline for special interest group (SIG) session submissions

Cogan awards, as well as the Joanne G. Angle Service and Kupfer Service awards.

Consider nominating a colleague for one or more of these prestigious awards before March 1, 2014.

There is no membership or geographical restrictions for nominees or nominators. Awards will be presented during the 2014 ARVO annual meeting.

To nominate a colleague or mentor, visit arvo.org/awards.

2014 ANNUAL MEETING

Under the banner of "Leading Eye and Vision Research," ARVO will host its 2014 annual meeting in Orlando, May 4 to 8.

Clinicians and researchers will come together to discover how eye and vision research is leading efforts in many related areas, including neuroscience, tissue imaging, and preventative health.

Abstract submissions are now being accepted through Dec. 6.

Learn more at arvo.org/am. ■



KATRINA NORFLEET is assistant director of communications for the Association for Research in Vision and Ophthalmology. Readers may contact her at 240/221-2924 or knorfleet@arvo.org.

IMPORTANT SAFETY INFORMATION FOR THE VERION™ REFERENCE UNIT AND VERION™ DIGITAL MARKER

CAUTION: Federal (USA) law restricts this device to sale by, or on the order of, a physician.

INTENDED USES: The VERION™ Reference Unit is a preoperative measurement device that captures and utilizes a high-resolution reference image of a patient's eye in order to determine the radii and corneal curvature of steep and flat axes, limbal position and diameter, pupil position and diameter, and corneal reflex position. In addition, the VERION™ Reference Unit provides preoperative surgical planning functions that utilize the reference image and preoperative measurements to assist with planning cataract surgical procedures, including the number and location of incisions and the appropriate intraocular lens using existing formulas. The VERION™ Reference Unit also supports the export of the high-resolution reference image, preoperative measurement data, and surgical plans for use with the VERION™ Digital Marker and other compatible devices through the use of a USB memory stick.

The VERION™ Digital Marker links to compatible surgical microscopes to display concurrently the reference and microscope images, allowing the surgeon to account for lateral and rotational eye movements. In addition, the planned capsulorhexis position and radius, IOL positioning, and implantation axis from the VERION™ Reference Unit surgical plan can be overlaid on a computer screen or the physician's microscope view.

CONTRAINDICATIONS: The following conditions may affect the accuracy of surgical plans prepared with the VERION™ Reference Unit: a pseudophakic eye, eye fixation problems, a non-intact cornea, or an irregular cornea. In addition, patients should refrain from wearing contact lenses during the reference measurement as this may interfere with the accuracy of the measurements.

Only trained personnel familiar with the process of IOL power calculation and astigmatism correction planning should use the VERION™ Reference Unit. Poor quality or inadequate biometer measurements will affect the accuracy of surgical plans prepared with the VERION™ Reference Unit.

The following contraindications may affect the proper functioning of the VERION™ Digital Marker: changes in a patient's eye between preoperative measurement and surgery, an irregular elliptic limbus (e.g., due to eye fixation during surgery, and bleeding or bloated conjunctiva due to anesthesia). In addition, the use of eye drops that constrict sclera vessels before or during surgery should be avoided.

WARNINGS: Only properly trained personnel should operate the VERION™ Reference Unit and VERION™ Digital Marker.

Only use the provided medical power supplies and data communication cable. The power supplies for the VERION™ Reference Unit and the VERION™ Digital Marker must be uninterruptible. Do not use these devices in combination with an extension cord. Do not cover any of the component devices while turned on.

Only use a VERION™ USB stick to transfer data. The VERION™ USB stick should only be connected to the VERION™ Reference Unit, the VERION™ Digital Marker, and other compatible devices. Do not disconnect the VERION™ USB stick from the VERION™ Reference Unit during shutdown of the system.

The VERION™ Reference Unit uses infrared light. Unless necessary, medical personnel and patients should avoid direct eye exposure to the emitted or reflected beam.

PRECAUTIONS: To ensure the accuracy of VERION™ Reference Unit measurements, device calibration and the reference measurement should be conducted in dimmed ambient light conditions. Only use the VERION™ Digital Marker in conjunction with compatible surgical microscopes.

ATTENTION: Refer to the user manuals for the VERION™ Reference Unit and the VERION™ Digital Marker for a complete description of proper use and maintenance of these devices, as well as a complete list of contraindications, warnings and precautions.

Alcon
a Novartis company

Knowing the osmolarity of your patient's tears is essential

The Gold Standard for the diagnosis and management of Dry Eye Disease.



CLIA WAIVED
Reimbursed at \$45.42/patient

by Medicare under the Laboratory Fee Schedule - CPT 83861 QW*



FDA 510(k) Cleared
(k083184)

CPT is a copyright and registered trademark of the American Medical Association (AMA).

*Please consult Medicare payment rules for your area; this is not an official guide on all matters pertaining to reimbursement.

©2013 TearLab Corp.
920132 REV C

How patient satisfaction plays role in IOL selection

Each lens may be best suited to specific subset based on individual preferences, sensitivities

By Fred Gebhart; Reviewed by Richard Chu, DO

TAKE-HOME

► A patient satisfaction and quality-of-life survey found that three presbyopia-correcting IOLs provide better spectacle independence than monovision.

FORT WORTH, TX ::

Ophthalmologists who might not be sure which IOL may be the best match for a particular patient have outside objective help.

Researchers presented what may be the first study to use patient satisfaction surveys to compare three FDA-approved presbyopic-correcting IOLs with validated test instruments.

Researchers used the National Eye Institute – Refractive Error Quality of Life – 42 (NEI-RQL-42) and the Subjective Vision Questionnaire (SVQ) to assess patient satisfaction with IOLs implanted for presbyopia.

The study, “Comparison of NEI-RQL-42 and SVQ quality of life measures after masked bilateral implantation of three FDA-approved presbyopia-correcting IOLs at 6-month follow-up,” investigated patient perceptions of the three lenses.

Patients were similarly satisfied with the overall visual results following implantation of either the Crystalens AO (AT-50AO, Bausch + Lomb), ReSTOR 3.0 (SN6AD1, Alcon Laboratories), or Tecnis Multifocal (ZMA00, Abbott Medical Optics), said lead author Richard Chu, DO, medical director, Chu Eye Institute, Fort Worth, TX.



Dr. Chu

Other results have showed very good and objective outcomes for all three lenses. In terms of patient perceptions, each of the three lenses had its own strengths and weaknesses that made it more, or less, helpful for specific subsets of patients.

“The results supported what we suspected based on lens designs,” Dr. Chu said. “Patients thought that the ReSTOR and Tecnis Multifocal had better near vision while the Crystalens had better distance vision and was better in terms of glare and halos, too.”

The surprising part was that all three lenses did well in patient satisfaction scores, all three did well in terms of spectacle independence, and all three scored better than monovision using the same validated assessment instrument, he added.

LACK OF CORRELATION

A second surprising finding was the lack of correlation between objective measurements of surgical results with each of the three lenses and subjective patient preferences, Dr. Chu said.

A comparison of patient satisfaction scores on the NEI-RQL Distance Vision Subscale and the measured residual spherical correction 6 months following implantation showed no relationship between subjective satisfaction and objective results. The r^2 was less than 0.3 for all three lenses.

The idea of patient satisfaction surveys is not new, Dr. Chu said.

The novel element in this study was the use of familiar and standardized quality of life and patient satisfaction instruments. Most practices develop their own survey questions or procedures—which means results cannot be compared across different studies, products, patient groups, or practices.

“We chose these two instruments because they have been used in many other studies and have been well validated,” Dr. Chu said. “The NEI-RQL, published in 2003, is more commonly used in America. The SVQ, which was published in Australia in 2004, is more familiar in other areas.”

Both of these surveys were designed for LASIK, but they measure many of the same limitations, symptoms, and side effects of post-refractive surgery that we are interested in following IOL implantation. Since there is not a survey designed specifically to evaluate IOLs,

these are the closest instruments available and the best validated, he noted.

THE PATIENT EXPERIENCE

One key message from the study is that patient perceptions of both their vision and specific side effects—such as glare and halos—are at least as important as objective measures.

Patients who value distance vision will probably be happier with a Crystalens or ReSTOR, which showed better satisfaction scores compared with Tecnis Multifocal (versus ReSTOR $p = 0.02$). Patients who value near vision will probably be happier with a ReSTOR or Tecnis Multifocal, both of which showed better satisfaction scores compared with Crystalens ($p = 0.13$ for ReSTOR and $p = 0.04$ for Tecnis Multifocal).

Patients who are bothered by glare might want to avoid Tecnis Multifocal, which showed significantly lower satisfaction scores at both 1 month and 6 months compared with Crystalens ($p < 0.01$ at 1 and 6 months) and ReSTOR ($p = 0.01$ at 1 month, $p = 0.04$ at 6 months). Glare scores improved for all three lenses from 1 to 6 months which suggests neuroadaptation.

All three lenses showed better spectacle independence at 1 month and 6 months than previously published monovision data.

“This study was really a way to quantify the patient experience with these three IOLs and get real world data in a quantifiable, analyzable manner,” Dr. Chu said. “In objective measures, these lenses all do pretty well.”

Lens selection really comes down to what the patient’s needs and preferences are, he noted.

“If you have a patient who is sensitive to glare and halo, for example, the Tecnis Multifocal would be the lens to avoid in that patient,” Dr. Chu said. “When new generations of lenses come out, we now know how to evaluate them in an apples to apples manner by using these same validated instruments.” ■

RICHARD CHU, DO

P: 817/346-7077 E: drrichard@chueye.com

Dr. Chu has financial interests in Bausch + Lomb.



Role in patient evaluation

Rapid tear film break-up time and central corneal staining in dry eye disease.

(Photo courtesy of Christopher E. Starr, MD)

DIAGNOSTIC SYSTEMS LAUNCH NEW ERA IN DRY EYE CARE

Technology platforms have higher sensitivity, specificity than traditional techniques for patient treatment

By Cheryl Guttman Krader; Reviewed by Christopher E. Starr, MD

take-home

► New diagnostic platforms for dry eye disease can help in determining the underlying cause and severity, which is useful for guiding treatment decisions.

NEW YORK ::

Recent technological advances are improving the diagnosis of dry eye disease and should enable more timely intervention that will help to reduce the morbidity of this common condition, according to Christopher E. Starr, MD.

“New diagnostic tests for dry eye not only are increasing [ophthalmologists’] ability to identify affected patients correctly, but also our ability to offer appropriate treatment,” explained Dr. Starr, associate professor of ophthalmology, Weill Cornell Medical College, New York.

“Using sensitive and specific objective testing takes the guesswork out of dry eye diagnosis—allowing clinicians to identify patients with significant disease who might otherwise have gone unnoticed or not treated aggressively enough,” he added.

The value of some new dry eye diagnostic platforms relates to their ability to identify two features of the disease:

- ▣ Hyperosmolarity, which is a core mechanism.
- ▣ Inflammation, which is a result of hyperosmolarity and a defining characteristic of dry eye disease.

The currently available point-of-care device for measuring tear film osmolarity now plays a central role in his practice as a screening and follow-up tool, Dr. Starr said.

Patients are first seen by a technician who asks a series of questions to elicit any symptoms potentially associated with dry eye disease.

Patients with any of the following symptoms will then undergo tear osmolarity testing before the eyes are exposed to any drops or lights.



Dr. Starr

- ▣ Grittiness on awakening
- ▣ Foreign body sensation
- ▣ Redness
- ▣ Tearing
- ▣ Burning
- ▣ Intermittent blurred vision
- ▣ Fluctuating vision

“Validated standardized questionnaires, such as the Ocular Surface Disease Index, are useful for research studies, but a bit too time-consuming to be practical for daily patient care,” Dr. Starr said. “We have developed a more streamlined approach to patient screening. Because we exclusively use an EMR for charting, a verbal, technician-driven, questionnaire is much faster and easier than scanning in the OSDI 45 times a day.”

Dr. Starr added that bilateral measurement of film osmolarity takes about 1 or 2 minutes, making it a lot faster than the Schirmer test.

In addition, unlike the Schirmer test, testing tear film osmolarity is reimbursable.

Dr. Starr noted that the Schirmer test as well as tear film breakup time (TBUT) and ocular surface staining still have a valuable role in patient evaluation as they can help to further determine the etiology of dry eye disease (aqueous tear deficiency versus evaporative).

However, having the symptom and osmolarity information available from the technician’s initial workup enables a directed, more efficient examination by the ophthalmologist and saves decision making time as well.

Continues on page 12 : **Diagnostics**

Reviewing evidence in dry eye treatment

Disorder should be approached in a stepwise fashion based the severity of condition

By **Fred Gebhart**; Deepinder K. Dhaliwal, MD, LAc

PITTSBURGH ::

DRY EYE DISEASE IS more complex than many ophthalmologists realize.

It is defined less by the clinical sign of cornea staining and more by patient symptoms of discomfort, visual disturbances and tear film instability that can lead to damage of the ocular surface.

"Many clinicians think that if there's no corneal staining, it can't be all that serious," said



Dr. Dhaliwal

Deepinder K. Dhaliwal, MD, LAc, associate professor of ophthalmology, director, Cornea and Refractive Surgery; director and founder, Center for Integrative Eye Care; director, UPMC Eye Center Monroeville; and medical director, UPMC LASER Vi-

sion Center, University of Pittsburgh Medical Center, Pittsburgh.

"The reality is that patients can and do can have dysfunctional tear syndrome with no clin-

ical signs and lots of symptoms," Dr. Dhaliwal said.

One key message, she said, is that the current definition of dry eye is based largely on visual disturbance, ocular discomfort, and other symptoms of tear film instability and that patients can have significant damage to the ocular surface with subtle clinical signs.

Dry eye is a multifactorial disease of the tears and the ocular surface. The multiplicity of causal and contributor factors and the broad range of symptoms give rise to a diverse menu of treatments.

Potential choices range from artificial tears to various gels and ointments, moisture chamber spectacles, anti-inflammatory agents, tetracyclines, punctal plugs, autologous, serum bandage contact lenses, and systemic immunosuppressives to multiple types of surgery.

Regardless of the specific symptoms a pa-

take-home

► An update is provided on the latest developments for an evidence-based approach in mild to severe dry eye disease.

tient might present, dry eye is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.

The only effective way to treat dry eye is to deal with the root cause of the problem. That starts by focusing on patient education, eliminating drying medications—such as systemic antihistamines—and reducing environmental irritants.

Dry eye is classified by stage:

■ **STAGE 1** is mild and/or episodic and usually occurs under stress. Visual symptoms are absent to episodic mild fatigue and there may be no clinical signs.

■ **STAGE 2** is moderate episodic or chronic and can occur with or without stress. Visual symptoms are annoying and can sometimes limit activity.

Continues on page 14 : Evidence

DIAGNOSTICS

(Continued from page 11)

Tear osmolarity not only makes a diagnosis of dry eye, it also helps in assessing its severity.

Dr. Starr considers any patient with a hyperosmolar tear film or significant tear instability to be a candidate for immunomodulatory therapy with topical cyclosporine A 0.05% emulsion (Restasis, Allergan).

"Hyperosmolarity leads to ocular surface inflammation and the vicious progressive cycle of damage as outlined in the DEWS report," he said. "My aim is to inhibit that process by therapeutic intervention, and cyclosporine is the only FDA-approved anti-inflammatory medication for treating dry eye.

"Even if patients have minimal symptoms but significant signs, such as hyperosmolarity or staining, proper therapy with cyclosporine should be initiated," Dr. Starr added. "Similarly, anti-inflammatory treatment should be

instituted in early stages of dry eye disease to prevent progression and potential ocular surface damage."

Dr. Starr said he also likes to utilize a short tapering course of loteprednol etabonate 0.5% gel (Lotemax gel, Bausch + Lomb) in conjunction with topical cyclosporine in patients with significant inflammation.

He also considers off-label use of topical azithromycin 1% (Azasite, Merck) for patients with dry eye disease associated with meibomian gland dysfunction or other forms of blepharitis because of the macrolide antibiotic's anti-inflammatory activity.

OTHER CONSIDERATIONS

Artificial tears also have a role in the management of all patients with dry eye disease, and Dr. Starr said he monitors frequency of their instillation along with changes in tear film osmolarity to determine treatment response.

A system for ocular surface interferometry that characterizes the tear film's lipid layer (LipiView, TearScience) is also available in

the United States for use in diagnosing dry eye. Though Dr. Starr does not have access to that technology yet, he hopes to have it soon. He believes it to be helpful for differentiating patients who have evaporative dry eye disease and for identifying patients who would benefit from treatment with the new thermal pulsation system for clearing meibomian gland obstruction (LipiFlow, TearScience).

Another platform that measures the level of matrix metalloproteinase-9 (MMP-9) in the tear film (InflammaDry, Rapid Pathogen Screening) is CE-marked and undergoing FDA review.

Dr. Starr said he intends to use it for diagnosis and follow-up when it becomes available, as studies show detection of elevated MMP-9 levels has very high sensitivity and specificity for diagnosing dry eye disease. ■

CHRISTOPHER E. STARR, MD

E: cestarr@med.cornell.edu

Dr. Starr is a consultant for Alcon Laboratories, Allergan, Bausch + Lomb, Merck, Nicox, Rapid Pathogen Screening, and TearLab.

For patients with decreased tear production presumed to be due to ocular inflammation associated with Chronic Dry Eye

RESTASIS[®] MAKES MORE OF THEIR OWN REAL TEARS POSSIBLE

Prescribe RESTASIS[®] for your appropriate moderate and severe Dry Eye patients and increase their own real tear production over time with continued use

For local co-pays,
scan QR-code or visit
restasiscopay.com



Indication and Usage

RESTASIS[®] (cyclosporine ophthalmic emulsion) 0.05% is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information

Contraindications

RESTASIS[®] is contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

Warnings and Precautions

Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, individuals prescribed RESTASIS[®] should not touch the vial tip to their eye or other surfaces.

Use With Contact Lenses: RESTASIS[®] should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion.

Adverse Reactions

In clinical trials, the most common adverse reaction following the use of RESTASIS[®] was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see Brief Summary of the full Prescribing Information on adjacent page.

RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%**BRIEF SUMMARY—PLEASE SEE THE RESTASIS® PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION.****INDICATION AND USAGE****RESTASIS®** ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.**CONTRAINDICATIONS****RESTASIS®** is contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.**WARNINGS AND PRECAUTIONS****Potential for Eye Injury and Contamination**

To avoid the potential for eye injury and contamination, be careful not to touch the vial tip to your eye or other surfaces.

Use with Contact Lenses**RESTASIS®** should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of **RESTASIS®** ophthalmic emulsion.**ADVERSE REACTIONS****Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical trials, the most common adverse reaction following the use of **RESTASIS®** was ocular burning (17%).

Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Post-marketing ExperienceThe following adverse reactions have been identified during post approval use of **RESTASIS®**. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Reported reactions have included: hypersensitivity (including eye swelling, urticaria, rare cases of severe angioedema, face swelling, tongue swelling, pharyngeal edema, and dyspnea); and superficial injury of the eye (from the vial tip touching the eye during administration).

USE IN SPECIFIC POPULATIONS**Pregnancy****Teratogenic Effects: Pregnancy Category C**Adverse effects were seen in reproduction studies in rats and rabbits only at dose levels toxic to dams. At toxic doses (rats at 30 mg/kg/day and rabbits at 100 mg/kg/day), cyclosporine oral solution, USP, was embryo- and fetotoxic as indicated by increased pre- and postnatal mortality and reduced fetal weight together with related skeletal retardations. These doses are 5,000 and 32,000 times greater (normalized to body surface area), respectively, than the daily human dose of one drop (approximately 28 mcL) of 0.05% **RESTASIS®** twice daily into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed. No evidence of embryofetal toxicity was observed in rats or rabbits receiving cyclosporine at oral doses up to 17 mg/kg/day or 30 mg/kg/day, respectively, during organogenesis. These doses in rats and rabbits are approximately 3,000 and 10,000 times greater (normalized to body surface area), respectively, than the daily human dose.

Offspring of rats receiving a 45 mg/kg/day oral dose of cyclosporine from Day 15 of pregnancy until Day 21 postpartum, a maternally toxic level, exhibited an increase in postnatal mortality; this dose is 7,000 times greater than the daily human topical dose (0.001 mg/kg/day) normalized to body surface area assuming that the entire dose is absorbed. No adverse events were observed at oral doses up to 15 mg/kg/day (2,000 times greater than the daily human dose).

There are no adequate and well-controlled studies of **RESTASIS®** in pregnant women. **RESTASIS®** should be administered to a pregnant woman only if clearly needed.**Nursing Mothers**Cyclosporine is known to be excreted in human milk following systemic administration, but excretion in human milk after topical treatment has not been investigated. Although blood concentrations are undetectable after topical administration of **RESTASIS®** ophthalmic emulsion, caution should be exercised when **RESTASIS®** is administered to a nursing woman.**Pediatric Use**The safety and efficacy of **RESTASIS®** ophthalmic emulsion have not been established in pediatric patients below the age of 16.**Geriatric Use**

No overall difference in safety or effectiveness has been observed between elderly and younger patients.

NONCLINICAL TOXICOLOGY**Carcinogenesis, Mutagenesis, Impairment of Fertility****Carcinogenesis:** Systemic carcinogenicity studies were carried out in male and female mice and rats. In the 78-week oral (diet) mouse study, at doses of 1, 4, and 16 mg/kg/day, evidence of a statistically significant trend was found for lymphocytic lymphomas in females, and the incidence of hepatocellular carcinomas in mid-dose males significantly exceeded the control value.In the 24-month oral (diet) rat study, conducted at 0.5, 2, and 8 mg/kg/day, pancreatic islet cell adenomas significantly exceeded the control rate in the low-dose level. The hepatocellular carcinomas and pancreatic islet cell adenomas were not dose related. The low doses in mice and rats are approximately 80 times greater (normalized to body surface area) than the daily human dose of one drop (approximately 28 mcL) of 0.05% **RESTASIS®** twice daily into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed.**Mutagenesis:** Cyclosporine has not been found to be mutagenic/genotoxic in the Ames Test, the V79-HGPRT Test, the micronucleus test in mice and Chinese hamsters, the chromosome-aberration tests in Chinese hamster bone-marrow, the mouse dominant lethal assay, and the DNA-repair test in sperm from treated mice. A study analyzing sister chromatid exchange (SCE) induction by cyclosporine using human lymphocytes *in vitro* gave indication of a positive effect (i.e., induction of SCE).**Impairment of Fertility:** No impairment in fertility was demonstrated in studies in male and female rats receiving oral doses of cyclosporine up to 15 mg/kg/day (approximately 2,000 times the human daily dose of 0.001 mg/kg/day normalized to body surface area) for 9 weeks (male) and 2 weeks (female) prior to mating.**PATIENT COUNSELING INFORMATION****Handling the Container**

Advise patients to not allow the tip of the vial to touch the eye or any surface, as this may contaminate the emulsion. To avoid the potential for injury to the eye, advise patients to not touch the vial tip to their eye.

Use with Contact Lenses**RESTASIS®** should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. Advise patients that if contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of **RESTASIS®** ophthalmic emulsion.**Administration**

Advise patients that the emulsion from one individual single-use vial is to be used immediately after opening for administration to one or both eyes, and the remaining contents should be discarded immediately after administration.

Rx Only

Based on package insert 71876US17

© 2013 Allergan, Inc.

Irvine, CA 92612, U.S.A.

® marks owned by Allergan, Inc.

APC37BD13

Patented. See www.allergan.com/products/patient_notices

Made in the U.S.A.

Special Report) DRY EYE**EVIDENCE***(Continued from page 12)***Clinical signs may or may not be present, but if present, staining is mild and the tear meniscus is somewhat reduced.****■ STAGE 3 is severe frequent or constant without stress. Visual symptoms are annoying, chronic to constant and limit activity. Clinical signs are moderate to marked conjunctival staining and marked central corneal staining and filamentary keratitis****■ STAGE 4 is severe and constant and may be disabling. Visual symptoms are constant and may be disabling. Clinical signs include conjunctival injection and marked staining, severe punctate erosions, scarring ulcerations and almost immediate tear break-up time.**

Treatment for dry eye is linked to the severity level, Dr. Dhaliwal said.

Stage 1 treatment is primarily education, environmental and dietary modifications, elimination of drying medications, artificial tears, gels or ointments, and eyelid therapy.

Environmental modifications are essential but not always easy. Patients should avoid drafts, which can be difficult if the workplace is directly under a heating or air conditioning vent. Computer screens may need to be repositioned so the patient can look down rather than straight ahead or up.

“Patients should not be using artificial tears every hour” Dr. Dhaliwal said.

That results in “dishpan” eyes, a condition like dishpan hands where all the natural oils have been washed away. Ophthalmologists need to treat the root cause of the dryness and not just tell patients to use artificial tears as often as they need. Get at the root cause of the disease, ocular surface inflammation.

Stage 2 dry eye needs more po-

tent treatment, typically anti-inflammatories. Cyclosporine can be effective, but can take 6 weeks to 3 months to reduce inflammation.

Dr. Dhaliwal said she typically combines cyclosporine with a mild topical steroid for the first 2 to 4 weeks to get a more immediate anti-inflammatory response.

Punctal plugs can help maintain the tear film once inflammation has resolved. Secretagogues and moisture chamber spectacles can also help.

Level 3 treatments add autologous serum, contact lenses and permanent punctal occlusion.

Level 4 disease requires systemic anti-inflammatories. If medical treatment does not work, the patient may need lid surgery, tarsorrhaphy, or transplantation of mucus membrane, salivary gland or amniotic membrane.

Proper diagnosis and stepwise treatment is an effort to prevent patients progressing to level 3 or level 4 dry eye, Dr. Dhaliwal said.

In addition to counseling patients to take basic steps to remedy potential environmental, dietary and medication causes as well as avoiding overuse of artificial tears, clinicians can suggest other easy and affordable interventions.

In patients that have associated meibomian gland dysfunction (with rapid tear break-up time), oral omega 3 fatty acids and warm compresses/lid massage are helpful.

Dr. Dhaliwal educates her patients to create a simple yet effective warm compress by placing a cup of uncooked rice into a clean cotton sock and heating it in the microwave for 30 seconds or so. This should be placed over the eyes for 15 minutes twice daily.

Also, if patients have significant dry eye symptoms first thing in the morning, be suspicious of lagophthalmos in which case patients do well with lubricating ointment at bedtime. ■

DEEPIK K. DHALIWAL, MD, LAC**P: 412/647-2200***Dr. Dhaliwal did not indicate a financial interest.*

SJÖGREN'S SYNDROME

(Continued from page 1)

an inflammatory eye disorder just like uveitis and it doesn't matter that one affects the ocular surface and the other the inside of the eye."

Though there is a need for guidelines that might direct practitioners in identifying which patients deserve further evaluation, available studies indicate that presence of dry mouth or other systemic complaints associated with other tissue damage from Sjögren's syndrome, as well as a family history of autoimmune disease, are useful predictors.

The possibility of Sjögren's syndrome should be considered in any patient with clinically significant dry eye described by the presence of ocular surface staining, or a low Schirmer test score, or a high tear film osmolarity.

take-home

► Since dry eye is an early presenting sign, eye-care providers need to maintain a high index of suspicion for Sjögren's syndrome in patients with clinically significant dry eye.

Then, a review of systems should be performed and patients should be asked about presence of dry mouth, joint pain, and a family history of autoimmune disease.

Any patient with these findings should have laboratory testing to diagnose Sjögren's syndrome.

A newer test is now available that identifies antibodies to salivary gland protein, carbonic anhydrase 6, and parotid secretory protein in addition to the traditional SSA, SSB, ANA and RF (Shen L et al. Novel autoantibodies in Sjögren's syndrome. *Clin Immunol.* 2012;145:251-255).

APPROACH TO MANAGEMENT

Patients whose dry eye is diagnosed with Sjögren's syndrome should be treated aggressively with anti-inflammatory treatment and followed at frequent intervals—even if their dry eye does not seem too severe, because they are at risk for developing extraglandular ocular complications.

"In a retrospective review of 183 patients with primary Sjögren's syndrome seen at our institution between 1999 and 2013, we found that one-third had extraglandular ocular findings," Dr. Akpek said. "Almost half of those patients had significant, vision-threatening disease, including corneal ulcer/infiltration, corneal melt/perforation, cicatrizing conjunctivitis, uveitis, optic neuritis, scleritis, and retinal vasculitis."

Patients with Sjögren's syndrome should also be referred to a rheumatologist for a full systemic evaluation and appropriate systemic treatment.

"Certain drugs used in the management of Sjögren's syndrome, such as hydroxychloroquine, can decrease the risk of lymphoma development," Dr. Akpek said. "Therefore, the ophthalmologist should always seek the col-

laboration of a rheumatologist in managing these patients." ■

ESEN AKPEK, MD

E: esakpek@jhmi.edu

Dr. Akpek has received institutional research grants from Alcon Laboratories and Allergan and is a consultant for Nicox.

Really?

Who has the experience to get you through Meaningful Use Stage 2?

EHR	Ophthalmology	Optometry	Total Attestations ¹
Medflow	1200	671	1871

The Numbers Speak For Themselves.

EHR	Total Attestations ²
MDOffice	255
EyeMD EMR Healthcare Systems	194
MDIntelleSys	115
NexTech	61

Medflow

Eyecare's Leading EHR Solution

www.medflow.com • 855-MEDFLOW

Register for our next Meaningful Use Stage 2 Webinar:
December 12 at 12:00 pm EST



The Medflow complete EHR is 2014 Edition compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of the U.S. Department of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services or guarantee the receipt of incentive payments.

Medflow EHR version 8.1

Certified 8/29/13, Version 8.1, Criteria Certified: 170.314(a)(1-15); 170.314(b)(1-5, 7); 170.314(c)(1-3); 170.314(d)(1-8); 170.314(e)(1-3); 170.314(f)(1-3); 170.314(g)(2-4) Clinical Quality Measures tested: CMS050v2; CMS062v2; CMS068v3; CMS069v2; CMS122v2; CMS127v2; CMS131v2; CMS132v2; CMS133v2; CMS138v2; CMS142v2; CMS143v2; CMS147v2; CMS156v2; CMS165v2; CMS167v2 Additional software used: NewCropRX, MS Excel, DataMotion, LDM Group

Price Transparency

Licensing and implementation of the functionality and content covered by this certification will require ongoing and/or one-time license and/or service fees covering the right to use the in-scope solutions, support, and requested standard implementation, integration, and consulting services. Required connectivity for transmitting patient data will require one-time costs, ongoing service fees, and/or transaction-based fees.

Source: [cms.gov](http://www.healthit.gov/sites/default/files/mu_report.csv) through July 2013 CMS recorded as of September 2, 2013
http://www.healthit.gov/sites/default/files/mu_report.csv

¹Medflow numbers include Medflow/Allscripts™ Doctors

²Ophthalmology and Optometry

Minimizing ocular surface problems can maximize refractive results

Screening process reveals higher rates of dry eye, blepharitis than most physicians anticipate

By William B. Trattler, MD, and Jodi Luchs, MD, Special to Ophthalmology Times

TWO PROSPECTIVE STUDIES

conducted recently both found that—though the majority of patients presenting for routine cataract surgery are asymptomatic—a large proportion of these patients do have clinically significant ocular surface disease.

If not addressed, tear film problems can lead to errors in IOL power selection, slow down healing and visual recovery, and reduce postoperative satisfaction and quality of vision, particularly in refractive cataract surgery with a premium IOL.

PHACO STUDY

The Prospective Health Assessment of Cataract Patients' Ocular Surface (P.H.A.C.O.) study was conducted at nine clinical sites across the United States.¹

In all, 136 patients (272 eyes) presenting for routine cataract surgery were examined for signs and symptoms of dry eye prior to surgery. The average age was 70 (range 54 to 87) years. About 22% of the patients had been told at some point in the past that they had dry eyes.

While experts debate what constitutes an abnormal tear film break-up time (TBUT), the typical values proposed as “abnormal” are <10 seconds or < 7 seconds.


However, most would agree that 5 seconds is too rapid. Surprisingly, the average TBUT in the PHACO study was 4.95 seconds, and 171 eyes (63%) had a TBUT of ≤ 5 seconds.

Most of the eyes (77%) had some corneal staining, but what was more concerning is that half of them had central corneal staining, which can certainly affect visual outcomes.

Although we generally view the Schirmer test as less useful for routine dry eye screening, one-fifth of the patients also had abnormally low Schirmer test scores (<5 mm) (Figure 1).

BLEPHARITIS STUDY

In another prospective study with very similar methodology, looking at the prevalence of bleph-



aritis, we (along with Carlos Buznego, MD) enrolled a total of 200 eyes of 100 patients presenting for routine biometry prior to cataract surgery.²

Following an ocular surface examination, 59% of the patients in this study had a diagnosis of blepharitis. Sixty-one percent had a TBUT of ≤ 7 seconds.

As cornea and external disease specialists, we aren't all that surprised by the results in either of these studies. What is striking is that the majority of the patients were asymptomatic or minimally symptomatic.

Although this surprised us initially, it does explain why ocular surface disease so often goes undiagnosed preoperatively. The patients are not complaining about it; the surgeon is focused on the primary complaint (cataract); and no one is really thinking about treating the ocular surface.

But failing to identify and treat dry eye prior to cataract surgery can lead to reduced visual outcomes. Either rapid TBUT or corneal staining will significantly affect keratometry and topography, reducing the accuracy of preoperative IOL power calculations. Ocular surface disturbances can



significantly alter the magnitude or axis of cylinder, affecting planning for limbal relaxing incisions or toric IOLs.

Moreover, once the cataract has been removed, visual fluctuations and quality-of-vision problems will become much more noticeable, even if the patient continues to be asymptomatic.

In the past, when patients expected to see 20/40 with glasses by 6 weeks, subtle ocular surface issues and even IOL power errors may not have mattered as much.

In today's environment, when patients undergo a 10- to 15-minute procedure under topical anesthesia and have the potential (with a premium IOL) for 20/20 distance and near acu-

Continues on page 18 : **Ocular surface**

take-home

► The majority of cataract patients likely have significant tear film disturbances that can affect their preoperative measurements and postoperative satisfaction with cataract surgery.



Satisfy and Retain Patients, Enhance Your Practice



 **LIPIVIEW®**
INTERFEROMETER



 **LIPIFLOW®**
THERMAL PULSATION



Dale Christianson
MCOA Eye Care
San Antonio, TX

Seize the Opportunity, Recognize the Impact of Meibomian Gland Dysfunction

"Eye care practices have an incredible business opportunity to better serve their existing patients who suffer from dry eye. By adopting the TearScience® Dry Eye Solution, we can now effectively treat evaporative dry eye, differentiate our practice by providing complete care, and grow our business through patient satisfaction and retention."

LipiFlow® is clinically proven and the only currently available medical device indicated for Meibomian Gland Dysfunction (MGD).

Visit tearscience.com for complete product and safety information.

*LipiFlow® and LipiView® are registered trademarks of TearScience®, Inc.
Copyright - TearScience® - The Evaporative Dry Eye Experts. All rights reserved.*

Special Report) DRY EYE

OCULAR SURFACE

(Continued from page 16)

ity within days of surgery, these subtle sources of error or visual compromises become much more relevant to successful management.

FIXING THE PROBLEM

Data suggest that cataract surgeons should have a high index of suspicion about dry eye and blepharitis and take steps to identify and treat these conditions prior to taking preoperative measurements for cataract surgery.

Short-term management of moderate dry eye or blepharitis to optimize the ocular surface for surgery is well within the skill set of any ophthalmologist. It does not require corneal training or specialized testing equipment, and it need not be time-consuming or disruptive to your preoperative flow.

Here are three steps that take only a few minutes preoperatively, but can save lots of chair time and headaches postoperatively:

- 1 Look for dry eye with corneal staining, TBUT, and topography.
- 2 Look for blepharitis/meibomian gland disease (MGD) by examining the lid margins and applying pressure to express the meibomian glands.
- 3 If you see rapid TBUT, MGD or corneal staining, treat the patient for 1 to 2 weeks before the biometry appointment with cyclosporine, topical steroids, nonpreserved artificial tears, and potentially punctal plugs (dry eye) and/or with warm compresses and topical azithromycin (blepharitis/MGD).

Alterations to the treatment regimen may be needed for longer-term management, but this regimen will get most patients in good enough shape for accurate biometry in a relatively short period.

IMPACT LARGE, SMALL

By routinely screening for ocular surface disorders—even in the absence of complaints—surgeons will be able to improve mean outcomes incrementally with premium IOLs across the board.

For patients for whom ocular sur-

face disorders might have led to a less-than-satisfactory outcome—the wrong IOL power implanted, for example—the impact can be great.

We often see unhappy postsurgical patients referred for consultation who simply have dry eye or blepharitis. Once the tear film is stabilized, visual quality improves dramatically and dissatisfaction disappears.

In one of Dr. Trattler's recent multifocal IOL patients, preoperative measurements pointed to a 20-D multifocal IOL (Tecnis Multifocal, Abbott Medical Optics) as the best choice. However, the topography had a lot of missing data, suggesting an unstable tear film.

Dr. Trattler elected to treat the patient with cyclosporine and topical steroids. When measurements were repeated 1 week later, keratometry had changed significantly. The patient received a 21-D lens and a great result from surgery.

In another case, a 58-year-old male with visually significant cataract in the left eye, who was interested in a premium IOL, we observe how the topography changes with treatment over just 1 day and 1 week (Figure 2).

CONCLUSIONS


Ocular surface disease in the cataract population is more common than most people believe. The majority of cataract patients likely have significant tear film disturbances that can affect their preoperative measurements and postoperative satisfaction with cataract surgery.

Given this, it is critical to have a high index of suspicion of dry eye and blepharitis. If ophthalmologists look for it even in asymptomatic patients, they can make the diagnosis and treat the ocular surface prior to surgery to maximize the chances of delivering the refractive results that patients expect. ■

References


- Trattler W, Reilly C, Goldberg D, Majmudar P, Vukich J, Packer M, Donnenfeld E. Cataract and dry eye: Prospective Health Assessment of Cataract Patients' Ocular Surface Study. Poster, American Society of Cataract and Refractive Surgery Annual Symposium and Congress. San Diego; March 2011.
- Luchs J, Buznego C, Trattler W. Incidence of blepharitis in patients scheduled for phacoemulsification. Presentation, American Society of Cataract and Refractive Surgery Annual Symposium and Congress. Boston; April 2010.

Figure 2 Preoperative Topography




A 58-year-old male with visually significant cataract OS, interested in a premium IOL.

Preop Topography After 1 Day of Treatment



Same patient: 1 day after starting lubricating drops.

Preop Topography After 1 Week of Treatment



Same patient: 1 week after initiating therapeutic agents for dry eye. (Images courtesy of William B. Trattler, MD)



WILLIAM B. TRATTLER, MD, is director of cornea, Center for Excellence in Eye Care, Miami, and volunteer assistant professor of ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. Readers may contact him at 305/598-2020 or wtrattler@gmail.com. Dr. Trattler is a consultant and speaker for Abbott Medical Optics, Allergan, and Bausch + Lomb.



JODI LUCHS, MD, is co-director, Department of Refractive Surgery, North Shore/Long Island Jewish Medical Center; director of cornea and external disease, South Shore Eye Care, Wantagh, NY; and assistant clinical professor of ophthalmology, Hofstra University School of Medicine, New York. Readers may contact him at 516/785-3900 or jluchs@aol.com. Dr. Luchs did not indicate any proprietary interest in the subject matter.

What's trending in dry eye research

Ophthalmologists, vision scientists track latest therapeutic, diagnostic advances in disease

By George Ousler and Ora Staff

THE PAST YEAR HAS been filled with many clinical updates in the dry eye arena. Perhaps nowhere was this more prevalent than in studies presented by ophthalmologists and vision researchers at the annual meeting of the Association for Research in Vision and Ophthalmology.

In an effort to understand the natural progression of dry eye disease in patients with moderate dry eye better, McDonnell et al. presented the design and baseline characteristics of the Progression of Ocular Findings (PROOF) study (*McDonnell P et al. IOVS 2013;54:ARVO E-Abstract 4338*).

The multicenter, prospective, 5-year, observational, case-controlled study is currently ongoing and enrolled 217 patients with Level 2 dry eye and 51 patients with no history of dry eye. Both groups are being followed every 6 months with a primary study endpoint of the percentage of patients with progression of dry eye from baseline to month 60.

Study evaluations include Schirmer test, TFBUT, OSDI, corneal and conjunctival staining, and goblet cell density. The authors noted that significant decreases in goblet cell density and increases in blurred vision were evident in this dry eye population.

Researchers also sought to report the prevalence of dry eye disease in the elderly French population (*Muselier-Mathieu A, et al. IOVS 2013;54:ARVO E-Abstract 877*).

The MONTRACHET (Maculopathy Optic Nerve nutrition neurovascular and HEArT diseases) study included 1,024 subjects over the age of 75 years. The prevalence of dry eye was evaluated with both subjective

criteria and objective criteria.

The study demonstrated that the prevalence of dry eye varies depending on the signs or symptom considered. For example, subjective criteria based on self-reported history of dry eye, use of topical medications, and OSDI scores of greater than 18 saw a dry eye prevalence of 17%, 11.9%, and 34%, respectively.

PHYSICAL ACTIVITY, SLEEP QUALITY

In a study designed to investigate the association among physical activity, sleep quality, and dry eye disease, the results indicated that both physical activity and sleep quality were associated with dry eye (*Kawashima M, et al. IOVS 2013;54:ARVO E-Abstract 940*). A high level of physical activity appears to lower the risk of dry eye, as more participants scored high in the physical activity in the non-dry eye group than in the dry eye group.

The researchers also concluded that poor sleep quality also appears to be an influencing factor of dry eye, particularly concerning dry eye symptoms.

SIGN, SYMPTOM ASSESSMENTS

Post-hoc data was presented from a prospective, two-center, randomized, double-masked, placebo-controlled phase II trial of MIM-D3 ophthalmic solution, a tyrosine kinase TrkA receptor agonist. In 150 patients with dry eye, those with greater or more rapid exacerbation of signs and symptoms from the CAE were more responsive to MIM-D3 (*Ousler G, et al. IOVS 2013;54:ARVO E-Abstract 4343*).

Continues on page 22 : **Trending**

take-home

► Research in dry eye disease continues to progress, fueled by studies in the area of therapies and diagnostics.



Parasol®



A PERFECT FIT

ODYSSEY MEDICAL + BEAVER VISITEC

The Odyssey Parasol® Punctal Occluder is now part of Beaver-Visitec International (BVI), a leader of trusted world ophthalmic brands. Not only is the Parasol® a perfect fit for your dry eye patients, but combining BVI with the outstanding success of the Parasol®, continues the tradition of superior knowledge, products and services.

For those of you who depend on a quality product from Odyssey Medical, **WELCOME TO BVI.**

Your new ordering information:

866-906-8080

customersupport@beaver-visitec.com

www.odysseymed.com

www.beaver-visitec.com

bvi Beaver Visitec
Keeping Your Vision in Sight

Beaver-Visitec International, Inc. | 411 Waverley Oaks Road Waltham, MA 02452 USA | BVI, BVI Logo and all other trademarks (unless noted otherwise) are property of a Beaver-Visitec International ("BVI") company © 2013 BVI

Managing MGD still a challenge

Maintenance is an important determinant for the efficacy of any intervention

By Cheryl Guttman Krader; Reviewed by Esen K. Akpek, MD

BALTIMORE ::

RECOGNITION AND TREATMENT of meibomian gland dysfunction (MGD) is important, because it is a common condition that can cause significant morbidity.

However, while a wide variety of therapeutic interventions are available for MGD, effective management remains a challenge.

Publication in 2011 of the proceedings from the International Workshop on Meibomian Gland Dysfunction ("MGD Workshop"), a project organized by the Tear Film Society and Ocular Surface Society, has raised awareness of MGD and the importance of identifying patients affected by what is considered to be the leading cause of dry eye.

Esen K. Akpek, MD, participated in the MGD Workshop as a member of the clinical trials committee, and she was also a co-author of a recently published Cochrane Database systematic review of interventions for chronic blepharitis.

"MGD is a chronic disease that can cause bothersome symptoms and serious corneal disease if there is progression to permanent gland atrophy," said Dr. Akpek, professor of ophthalmology and rheumatology, and director, ocular surface disease and dry eye clinic, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore.

LID HYGIENE

"Lid hygiene measures definitely are effective treatment for MGD, and various other interventions, including pharmaceutical treat-

ments, have been shown to work when evaluated over a short testing period," Dr. Akpek said. "However, effective management of MGD requires adherence to maintenance therapy, and that is probably why it is such a difficult therapeutic problem."

Lid hygiene measures using eyelid warming and mechanical lid hygiene to express MG secretions are widely considered effective for MGD even though there is no standard technique or studies comparing specific techniques for lid hygiene.

Nevertheless, it is generally agreed that patients should be advised about lid hygiene and followed for their compliance, Dr. Akpek said.

"There are some newer device-based approaches for addressing MG obstruction, including a thermal-pulsation device, intense pulsed light treatment, and gland probing," she said. "These interventions have been shown to lead to some improvement."

"However, any remission is not permanent, and these interventions are expensive and often not covered by insurance," she added.

OTHER THERAPIES

Artificial lubricant therapy has been more widely studied for treating aqueous tear deficiency than for evaporative tear deficiency that occurs with MGD. Based on available evidence, it may be reasonable to recommend use of higher-viscosity products to patients with MGD, Dr. Akpek said.

Topical lipid supplements in

Continues on page 22 : **Manage MGD**

Visit us at AAO Booth #4012



How can my practice...

ensure quality patient care,
earn patient appreciation,
and **increase** revenue?



Consider OASIS®
products for your practice.

More than expected

Oasis is dedicated to equipping eye care providers with effective solutions to ensure quality patient care, improve practice management, and support practice growth.



Find out more about how we can help your practice.

www.oasismedical.com

800-528-9786 (USA Toll Free)

909-305-5400



OASIS name and logo are registered trademarks of OASIS Medical, Inc.
514 S. Vermont Ave, Glendora, CA 91741. REV3-82913

WELCOME TO THE ERA OF CENTURION®

Optimize every moment of your cataract removal procedure with the NEW CENTURION® Vision System.

Active Fluidics™

Automatically optimizes chamber stability by allowing surgeons to customize and control IOP throughout the procedure.

Balanced Energy™

Enhances cataract emulsification efficiency using OZil® Intelligent Phaco and the new INTREPID® Balanced Tip design.

Applied Integration™

Designed to work seamlessly with other Alcon technologies for an integrated cataract procedure experience.



Learn more about the new era of cataract procedures.
Visit MyAlcon.com.

Alcon
a Novartis company


CENTURION
VISION SYSTEM

Special Report) **DRY EYE****TRENDING**

(Continued from page 19)

What's more, patients who reported having dry eye for 5 to 10 years saw a significant reduction in fluorescein staining and experienced improvements in symptoms, as opposed to those patients who reported having dry eye for 1 to 5 years or >10 years (Meerovich K, et al. IOVS 2013;54:ARVO E-Abstract 4340).

Positive data on thymosin beta 4 (Tβ4) was presented (Sosne G et al. IOVS 2013;54:ARVO E-Abstract 6033). In the physician-sponsored phase II study, 9 patients with severe dry eye were treated with Tβ4 eye drops (0.1%) or vehicle control 6 times daily over 28 days.

Dry eye sign and symptom as-

sessments were evaluated throughout the study. Tβ4 drops were safe and well-tolerated and statistically significant differences in sign and symptom assessments were seen at various time points. The authors noted that further trials are warranted to assess optimal dosing regimens.

BIOMARKERS

One prominent clinical methodology theme for ocular inflammation was the measurement of biomarkers of disease with a focus on those found in tears. Several groups (Hagan S et al. IOVS 2013;54:ARVO E-Abstract 955; Enriquez-De-Salamanca A et al. IOVS 2013;54:ARVO E-Abstract 2072; Dionne K et al. IOVS 2013;54:ARVO E-Abstract 4324; Lakshman N et al. IOVS 2013;54:ARVO E-Abstract 4325) sought to indentify both normal and pathological values

for cytokines in tears. Though there were some disagreements between studies on the quantitative metrics, it is clear that the tools to measure picogram quantities of signaling molecules accurately are up-and-coming.

TEAR FILM STABILITY

Other presentations focused on the importance of blink, mucin function, and dry eye tests of tear film stability.

Researchers examined the importance of considering lid contact time to differentiate dry eye and normal subjects (Lafond A et al. IOVS 2013;54:ARVO E-Abstract 962). The authors found that dry eye subjects had significantly longer lid contact times and contact rates than normal subjects. The automated capture of blink and the relative ease of

this technology allows for the tracking of spontaneous blink activity. Mucin function in dry eye was also the subject of multiple presentations.

Another presentation found that as the signs of dry eye worsen, soluble MUC16 values increase (Watson M, et al. IOVS 2013;54:ARVO E-Abstract 4309).

Additionally, Saigal et al. presented data on the correlations of dry eye signs to signs, symptoms to symptoms, and both to objective tests of tear film stability. The authors reported the correlation of many signs and symptoms and quality-of-life variables (Saigal S, et al. IOVS 2013;54:ARVO E-Abstract 4361). ■



GEORGE W. OUSLER III is vice president of dry eye at Ora Inc., Andover, MA.

IMPORTANT SAFETY INFORMATION

CAUTION: Federal (USA) law restricts this device to sale by, or on the order of, a physician.

As part of a properly maintained surgical environment, it is recommended that a backup IOL Injector be made available in the event the AutoSert® IOL Injector Handpiece does not perform as expected.

INDICATION: The CENTURION® Vision System is indicated for emulsification, separation, irrigation, and aspiration of cataracts, residual cortical material and lens epithelial cells, vitreous aspiration and cutting associated with anterior vitrectomy, bipolar coagulation, and intraocular lens injection. The AutoSert® IOL Injector Handpiece is intended to deliver qualified AcrySof® intraocular lenses into the eye following cataract removal.

The AutoSert® IOL Injector Handpiece achieves the functionality of injection of intraocular lenses. The AutoSert® IOL Injector Handpiece is indicated for use with the AcrySof® lenses SN60WF, SN6AD1, SN6AT3 through SN6AT9, as well as approved AcrySof® lenses that are specifically indicated for use with this inserter, as indicated in the approved labeling of those lenses.

WARNINGS: Appropriate use of CENTURION® Vision System parameters and accessories is important for successful procedures. Use of low vacuum limits, low flow rates, low bottle heights, high power settings, extended power usage, power usage during occlusion conditions (beeping tones), failure to sufficiently aspirate viscoelastic prior to using power, excessively tight incisions, and combinations of the above actions may result in significant temperature increases at incision site and inside the eye, and lead to severe thermal eye tissue damage.

Good clinical practice dictates the testing for adequate irrigation and aspiration flow prior to entering the eye. Ensure that tubings are not occluded or pinched during any phase of operation.

The consumables used in conjunction with ALCON® instrument products constitute a complete surgical system. Use of consumables and handpieces other than those manufactured by Alcon may affect system performance and create potential hazards.

AEs/COMPLICATIONS: Inadvertent actuation of Prime or Tune while a handpiece is in the eye can create a hazardous condition that may result in patient injury. During any ultrasonic procedure, metal particles may result from inadvertent touching of the ultrasonic tip with a second instrument. Another potential source of metal particles resulting from any ultrasonic handpiece may be the result of ultrasonic energy causing micro abrasion of the ultrasonic tip.

ATTENTION: Refer to the Directions for Use and Operator's Manual for a complete listing of indications, warnings, cautions and notes.

Alcon
a Novartis company

MANAGE MGD

(Continued from page 20)

various formulations have been demonstrated to improve the signs and symptoms of MGD, probably by improving tear film stability. Topical antibiotics (azithromycin and metronidazole) and oral antibiotics (tetracycline derivatives) are also used and may provide benefit through both antimicrobial and anti-inflammatory actions.

Though there is some evidence of their efficacy, more solid proof from trials is missing, she said.

Lid scrubs containing tea tree oil, which eradicates Demodex, are also marketed for the treatment of MGD based on a suggested pathophysiologic role of infestation with these mites. Understanding of the relationship between Demodex and MGD is incomplete and there is a lack of good scientific evidence supporting use of tea tree oil scrubs for MGD treatment alone.

Tea tree oil also has antibacterial,

antifungal, and anti-inflammatory properties that may be beneficial, and it has been shown to reduce symptoms of surface inflammation.

Topical corticosteroids have also been used as a treatment for MGD. Their use is controversial because of the potential for complications, but topical corticosteroids may be considered to have a role in managing acute inflammation, such as in patients with marginal hypersensitivity keratitis, or as an intralesional injection for chalazia.

Oral supplementation with essential fatty acids, including omega-3 and omega-6 fatty acids, is another popular recommendation for MGD management and also somewhat controversial, because there is conflicting evidence on the efficacy of these supplements and no clear information on necessary doses. ■

ESEN K. AKPEK, MD

E: esakpek@jhmi.edu

Dr. Akpek has received institutional research grants from Alcon Laboratories and Allergan and is a consultant for Nicox. She was an unpaid member of the MGD Workshop.

New IOL technology yields lack of glistening formation

Surgeon's personal experience with lens also advantageous to explaining procedure to patients

By Lynda Charters; Reviewed by Lawrence R. Goldberg, MD

TAKE-HOME

► **The absence of glistening formation is among the advantages associated with new IOL technology, relates one ophthalmologist.**

ST. PETERSBURG, FL ::

A new glistening-free, hydrophobic acrylic (enVista, Bausch + Lomb) seems to be a step forward in IOL technology in that it has major advantages and very few disadvantages, according to one ophthalmologist.

Though the IOL is relatively new to the market, Lawrence R. Goldberg, MD, is enthusiastic about its performance.

The hydrophobic acrylic IOL is designed to provide visual correction of aphakia in adults who have undergone removal of a cataractous crystalline lens with powers that range from 0 to +34 D. The lens is J-shaped, foldable, and very clear with no tint, which Dr. Goldberg prefers. Because this lens is not a premium IOL, it is covered by insurance.



Dr. Goldberg

By far the greatest benefit of this IOL is that it is glistening-free, according to Dr. Goldberg. He previously used the SN60WF IOL (Alcon Laboratories) almost exclusively in his practice, however, the major drawback of that IOL was the formation of glistenings.

From 10% to 15% of patients had a significant formation of glistenings throughout the lens, he noted.

"The glistenings were so extensive that it might affect contrast sensitivity even though the visual acuity was 20/20 to 20/25," he said.

ABSENCE OF GLISTENING FORMATION

With the introduction of the new hydrophobic acrylic IOL slightly over a year ago, Dr. Goldberg was impressed by the reported absence of glistening formation and began to use the lens in his practice in St. Petersburg, FL.

"I liked what I saw with my patients, and no glistenings have formed in the lenses," Dr. Goldberg said. "However, right now, it is too early to state that glistenings will never form because they usually form about 1 or 2 years after implantation in the SN50WF IOL."

Thus far, his patients have had no problems with the IOL postoperatively. The lenses have remained crystal clear. The IOL is stable in the bag, and all patients in a study sponsored by

the manufacturer had 5° or less of IOL rotation between days 30 and 180 after implantation.

RESISTANT TO SCRATCHES AND ABRASIONS

Another advantage is that the lens is scratch- and abrasion-resistant, Dr. Goldberg noted.

"It is a tough lens that does not scratch or tear," he said. "The SN60WF IOL can tear occasionally, because it gets caught in the injector and I would have to pull it out."

Dr. Goldberg also has noted the occurrence of small cracks in the optic after uneventful injection of the SN60WF IOL into the capsular bag in a few patients.

"The enVista lens pops out of the injector smoothly," he said. "It has a harder surface and does not scratch or crack."

The IOL also has an aberration-free aspheric optic that enhances contrast sensitivity. Posterior capsular opacification should be minimal because of the IOL's 360° square posterior edge and step-vaulted haptics for direct contact with the capsular bag.

The IOL can be inserted through a 2.2-mm wound assist or a 2.4-mm in-the-bag incision during a standard phacoemulsification procedure. The only drawback to the hydrophobic acrylic IOL is that compared with other IOLs,

Continues on page 24 : Glistening-free



Brought to you by

Ophthalmology Times

Optometry Times



modernmedicine.com/iTech
Resource Center for Technician Education

WEB EXCLUSIVE CONTENT

Related Articles | Continuing Education | Clinical Tools & Tips

iTech provides educational presentations and information for ophthalmic and optometric technicians, helping them work effectively with their doctors to enhance the practice.

GLISTENING-FREE

(Continued from page 23)

it unfolds slowly because it is a bit stiffer, according to Dr. Goldberg.

However, this is not a deal-breaker for him. "Because it is stiffer, the IOL will hold up better in the event of a trauma if the injection process is not perfect," he said.


Dr. Goldberg also has first-hand experience with the lens, and he sees this as an advantage when explaining the cataract procedure. ■

Surgeon has lens implanted in his eyes

RESULTS ACHIEVED WITH the hydrophobic acrylic IOL (enVista, Bausch + Lomb) have impressed Lawrence R. Goldberg, MD, so much so that it was the lens of choice for his own bilateral cataract surgeries—especially because of the absence of glistening formation and positive feedback from colleagues.

Surgery on the right eye was performed July 19 and that on the left eye Aug. 13, 2013, to address a nuclear cataract and a posterior sub-capsular cataract.

The cataract in the right eye was substantially worse, and the vision had decreased to about 20/40 without glare testing. The vision in the other eye was still 20/20.



The hydrophobic acrylic IOL became the lens of choice for Dr. Goldberg's own bilateral cataract surgery. (Photo courtesy of Lawrence R. Goldberg, MD)

After undergoing surgery in the right eyes, Dr. Goldberg's eyeglass correction had gone from 5 D of hyperopia preoperatively (a similar correction was present in his left eye) to a spherical equivalent of plano 1 week postoperatively.

Due to significant anisometropia, Dr. Goldberg was unable to wear a temporary lens in his right eye along with his highly hyperopic lens in his left eye. He decided to have surgery 1 month later in his left eye despite the 20/20 corrected vision in that eye. Between surgeries, Dr. Goldberg noticed how much brighter vision was in the right eye with the IOL implanted compared with the fellow eye.

Dr. Goldberg no longer needs to wear glasses to correct the preoperative hyperopia. "My distance vision is great, even without glasses," he said. "I have a small amount of distance correction and I will add to the progressive lens power so that I don't have to take the glasses on and off for reading. However, I can still read a little without the glasses." ■

LAWRENCE R. GOLDBERG, MD

E: rhinoeye@yahoo.com

Dr. Goldberg has no proprietary interest in the technology.

GLAUCOMA RESEARCH FOUNDATION
GLAUCOMA 360

NEW HORIZONS FORUM

REGISTER NOW

for the 3rd Annual New Horizons Forum
at www.glaucoma360.org

Early Bird Registration Open Until December 15


February 7, 2014

The Palace Hotel • San Francisco, CA

Speeding the development of new therapies
and diagnostics for glaucoma patients

Keynote Speaker: Robert N. Weinreb, MD

Chairman & Distinguished Professor of Ophthalmology, Director, Shiley Eye Center, UCSF



"Best meeting to see what is happening in glaucoma
from surgery to new drugs to drug delivery systems."

Alan S. Crandall, MD, University of Utah

GLAUCOMA
RESEARCH FOUNDATION

251 Post Street, Suite 600, San Francisco, CA 94108 (415) 986-3162 www.glaucoma.org



Building the Ophthalmic Tech's Community of Practice

modernmedicine.com/iTech

Resource Center for Technician Education

WEB EXCLUSIVE CONTENT

Related Articles | Continuing Education | Clinical Tools & Tips

iTech provides educational presentations and information for ophthalmic and optometric technicians, helping them work effectively with their doctors to enhance the practice.



Brought to you by **Ophthalmology Times & Optometry Times**



Combined steroids, anti-VEGFs show promise in DME patients

Adding dexamethasone implant to bevacizumab resulted in lower subfield thickness, OCT volume

By Michelle Dalton, ELS; Reviewed by Raj K. Maturi, MD

TAKE-HOME

► For some patients with diabetic macular edema, treatment with anti-vascular endothelial growth factor agents may not be enough. Clinicians need to consider other options, including dexamethasone implants.

INDIANAPOLIS ::

Anti-vascular endothelial growth factor (VEGF) agents alone may not provide the optimal response for all patients with diabetic macular edema (DME). This was evident with only 50% of the subjects in the Diabetic Retinopathy Clinical Research Network's Protocol I monthly ranibizumab group achieving a 2-line improvement in visual acuity after 2 years.

Because steroids provide a different mechanism of action, combining steroids with anti-VEGFs "may be more efficacious than either treatment alone in those patients without a complete response," said Raj K. Maturi, MD, in private practice at Midwest Eye Institute and with the Department of Ophthalmology, Indiana University School of Medicine, Indianapolis.


Protocol I also found 40% were unable to achieve macular flattening at year 2, despite the protocol-mandated monthly evaluation and treatment, Dr. Maturi noted.

Protocol I (as well as the RISE/RIDE and RESTORE, the extension study for RISE/RIDE) "shows that if patients don't get the required treatment over time, they will lose out. If they don't come in consistently, they are losing out," Dr. Maturi said.

Optical coherence tomography (OCT) showed a continued thickening in a significant num-

Continues on page 28 : DME

Changes In Macular Edema Over Time



(FIGURE 1) One subject who was unsuccessfully treated with bevacizumab showed a marked improvement with the addition of dexamethasone. This patient was randomly assigned to the bevacizumab alone arm, but had to be rescued with dexamethasone implant at month 7.

(FIGURE 2) A subject with both eyes in the study showed a much more complete resolution of edema in the left eye compared with the right. Visual acuity gain was similar. (Figures courtesy of Raj K. Maturi, MD)



Dr. Maturi

Current Concepts in **Ophthalmology**

Presented by

**The Wilmer Eye Institute at
Johns Hopkins University School of Medicine**

Activity Directors:

Walter J. Stark, MD and Neil M. Bressler, MD

*Baltimore,
Maryland*

December 5-7, 2013

*Johns Hopkins University
School of Medicine
Thomas B. Turner Building*



Topics :

- Glaucoma
- Cataract and Anterior Segment Surgery
- Laser-Assisted Cataract Surgery
- Management of IOL Complications
- Macular Degeneration and Diabetic Retinopathy
- Oculoplastics
- Refractive Surgery
- Practice Management
- Descemet's Stripping and Descemet's Membrane Endothelial Keratoplasty

Special Features:

- OCT
- Non-Surgical Facial Rejuvenation
- Coding and Reimbursement

*Vail,
Colorado*

March 9-14, 2014

Vail Marriott

Supported by:

Ophthalmology Times

All the Clinical News in Sight

Mark Your Calendar!

The 73rd Wilmer Residents Association Clinical Meeting

June 13, 2014

Johns Hopkins University, School of Medicine, Thomas B. Turner Building

Call (410) 502-9635 for more information

For further information, please contact:

Office of Continuing Medical Education

Johns Hopkins University

720 Rutland Avenue, Turner 20

Baltimore, Maryland 21205-2195

P: (410) 502-9636

F: (866) 510-7088

cmenet@jhmi.edu • www.HopkinsCME.edu

DME

(Continued from page 26)

ber of subjects at 12 months in both the ranibizumab arms (0.3 and 0.5 mg).

POTENTIAL ROLE FOR STEROID COMBINATIONS

Dr. Maturi and colleagues—through a study supported by an Investigator Initiated Trial grant from Allergan—randomly assigned 40 eyes of 30 patients in a prospective, subject-masked, single-center study to evaluate the combination of dexamethasone and bevacizumab 1.25 mg (Group 1) versus bevacizumab 1.25 mg alone (Group 2).

In both groups, treatment was withheld if OCT was less than 250 μm and the acuity was better than 20/20. Both groups also received an initial bevacizumab injection.

Group 2 continued to receive monthly injections while Group 1 received dexamethasone intravitreal implant at month 1, 5, 10 and re-treated with bevacizumab at other visits.

The main inclusion criteria included a best-corrected visual acuity (BCVA) score between 24 and 78 letters and the presence of DME, defined as time domain equivalent OCT $>250 \mu\text{m}$.

Subjects with two eligible eyes had one eye randomly assigned to one treatment arm and the second eye to the other treatment arm. Ninety percent of those in Group 1 ($n = 21$)

and 95% of those in Group 2 ($n = 19$) had type 2 diabetes.

There were more female ($n = 17$) than males, and the subject group was overwhelmingly Caucasian ($n = 28$).

At baseline, OCT central subfield thickness was slightly greater in Group 2.

Both groups gained about 5 letters, but it is the OCT changes that are “markedly different between the groups,” Dr. Maturi said. “More patients in the combination group had macular flattening (OCT central thickness less than 250 μm) at 6 months with a change from baseline $>25 \mu\text{m}$ (80% in the combination, versus 44% in the bevacizumab-alone groups).”

Additionally, the patients in the combination treatment group needed fewer supplemental treatments of bevacizumab.

“What we found was the overall edema resolution was much more complete in Group 1—volume is 10.4 mm^3 versus 11.3 mm^3 in the bevacizumab-only arm,” Dr. Maturi said. “The dexamethasone intravitreal implant is most effective in the first 3 months after injection and less effective in the fourth month in reducing edema.”

Monthly additions of bevacizumab during the subsequent 3 months “did not seem to have much affect on the duration of response,” Dr. Maturi added.

For an example, see Figure 1 on Page 26 (a subject who was randomly assigned to Group 1, but her severe edema was unsuccessfully treated with anti-VEGFs and she required rescue with the dexamethasone implant).

In Figure 2 on Page 26, one patient with both eyes enrolled showed much better results in the combination arm than in the bevacizumab-only arm.

Dr. Maturi pointed out that the patients who had undergone the most bevacizumab injections prior to study enrollment gained the most vision when in the dexamethasone arm.

“There are some areas of caution with the use of dexamethasone (or other steroid),” Dr. Maturi said. “Steroids can cause an increase in IOP (6 of the 20 eyes in the steroid arm needed topical treatment for pressure control), and cataract progression can occur—almost half the eyes in the steroid group had progression of cataract.

However, these are known and manageable complications that the patient and physician are generally quite aware of, Dr. Maturi noted.

“Clinicians need to know that the anti-VEGFs don’t work on everyone—about 30% will have continued edema despite 6 months or more of treatment,” Dr. Maturi said. “We need to think about other options for these patients and dexamethasone implants are an excellent choice.”

Dr. Maturi suggested these findings warrant a larger, phase III study. ■

RAJ K. MATURI, MD

P: 317/817-1423

E: rmaturi@gmail.com

Dr. Maturi is a consultant for Allergan and Allergan provided financial support for the study and had no control on the results or submission. The statistical analysis was performed at the JAEB Center, Tampa, FL.

R-Tech RP study enrollment complete

By Rose Schneider

BETHESDA, MD ::

SUCAMPO HAS ANNOUNCED that its development partner, R-Tech Ueno Ltd., has completed the enrollment of a phase III study for its treatment of retinitis pigmentosa (RP).

R-Tech is conducting the clinical trial of unoprostone isopropyl ophthalmic solution 0.15% at 38 medical institutions in Japan.

The randomized, double-blind, placebo-controlled study will evaluate whether the treatment improves central retinal sensitivity as determined by Humphrey Field Analyzer in patients with RP.

The study’s primary endpoint is the value of mean retinal sensitivity at four central points at 1 year.

The target sample size is 180 patients.

“There are no drugs currently approved for the treatment of RP anywhere in the world, and we believe that unoprostone isopropyl may be a promising candidate for this indication,” said Ryuji Ueno, MD, PhD, chairman, chief executive officer, and chief scientific officer of Sucampo.

With the completion of the phase III trial enrollment, Dr. Ueno said R-Tech expects to complete the study by the end of 2014, with results available in early 2015.

“Upon successful results, Sucampo intends to work with regulatory authorities in the United States and the European Union to determine

the incremental data that will be necessary to form application packages for each region,” he said. “We look forward to the possibility of helping to meet the unmet needs of patients suffering from RP in these countries.”

The study is being funded through an agreement between R-Tech and the Japan Science and Technology Agency.

Sucampo licensed from R-Tech the exclusive development and commercialization rights to the treatment globally except for Japan, China, Taiwan, and Korea.

Both the FDA and the European Medicines Agency have granted orphan drug designation to the treatment. ■

GO TO products.modernmedicine.comModernMedicine
NETWORK

DIGITAL IMAGING

Digital Fluorescein Angiography (FA) Upgrades for Zeiss FF 450 & All Topcon 50 Series Systems

Carolina Ophthalmics, a leader in ophthalmic imaging, announces digital fluorescein angiography (FA) upgrades for the new Zeiss FF 450 & all TOPCON 50 series systems. With an excellent rate of \$9,995, feature upgrades include 21.1 megapixels with Canon 5D Mark II, iMACAM™ SQL Database Software, Windows 7/8 PC or Laptop with backup drive.

Carolina Ophthalmics uses iMACAM™ imaging/database software with all systems, and also offers older image data conversion to iMACAM™ SQL database, addition to DICOM file output, Fundus Auto Fluorescent (FAF) upgrades, non-myd retinal system upgrades, digital slit lamp upgrades, and iPAPERLESS™ instrument integration.

Carolina Ophthalmics

888-393-4624 | sales@iMACAM.net | www.iMACAM.netGo to [products.modernmedicine.com/Digital Fluorescein Angiography](http://products.modernmedicine.com/Digital-Fluorescein-Angiography)

EDUCATIONAL SUPPLEMENTS

iTech Supplement Is A Resource for Technician Education

iTech, a print and digital supplement produced by Ophthalmology Times, provides educational presentations and information for ophthalmic and optometric technicians. Distributed quarterly, iTech will be available in March, June, September and December 2014 and will cover key clinical data and practice management tips to optimize patient care. Include your information today!



Karen Gerome

440-891-2670 | kgerome@advanstar.comGo to modernmedicine.com/itech

SOCIAL MEDIA

Social Media Offers Breaking Ophthalmic and Optometric News

Ophthalmology Times clinical news and insight is now available on Facebook and Twitter. Offering the latest breaking news, announcements and events, the clinical social media pages allows you to be the first to know what's happening from the ophthalmic news authority. Visit the pages today!

Karen Gerome

440-891-2670 | kgerome@advanstar.comGo to facebook.com/OphthalmologyTimesGo to twitter.com/ophthtimes

PRODUCT WATCH

Product Watch Enhances Exposure to Key Purchase-Making Physicians

Product Watch marketplace, built by Ophthalmology Times, offers product exposure to purchase-making physicians while boosting presence at major tradeshow. Designed to feature exhibiting products, the Product Watch section displays product image, product description, product website and contact information. Additionally, a one-time email push to the print and digital audience of Ophthalmology Times enhances product awareness. Contact us to include your product today!

Karen Gerome

440-891-2670 | kgerome@advanstar.comGo to products.modernmedicine.com

marketplace

For Products & Services advertising information, contact: **Karen Gerome** at 800-225-4569, ext 2670 • Fax 440-756-5271 • Email: kgerome@advanstar.com

For Recruitment advertising information, contact: **Joanna Shippoli** at 800-225-4569, ext 2615 • Fax 440-756-5271 • Email: jshippoli@advanstar.com

PRODUCTS & SERVICES

BILLING SERVICES

PM Medical Billing & Consulting

Exclusive Ophthalmology Billers
Expert Ophthalmology Billers
Excellent Ophthalmology Billers
Triple E = Everything gets Paid

Concentrating on one Specialty makes the difference.

We are a Nationwide Ophthalmology Billing Service. We have been in business over twenty years. Our staff consists of billers who are certified Ophthalmic Techs, Ophthalmic assistants, and fundus photographers who are dual certified ophthalmic coders and billers. This combination of clinical backgrounds in ophthalmology with the certified coding degree is the ideal combination of expertise that you need to dramatically increase your revenue. We will get you paid on every procedure every single time. No more bundling, downcoding or denials...

Primary, Secondary, Tertiary and Patient Billing
Relentless and meticulous follow up.

- Experts in Forensic Billing .Specializing in old AR cleanup
- Credentialing and Re credentialing our Specialty. We have a separate Credentialing Department who has cultivated years of contacts to expedite the process as well as getting providers on plans that are technically closed.
- We can offer you our own Practice Management software at no cost to you or we can VPN into your system if that is what you prefer.
- Totally Hipaa compliant. We are certified Hipaa and have invested in the most secure Hipaa connection that Google and Cisco use.
- Monthly custom reports provided.

We presently work on all of the following Practice Management systems :

NextGen, MD Office, Centricity, Medisoft, Office Mate, MD Intellus, Medware, Medcomp, Management Plus, ADS, Revolution EHR, EyeMd EMR, Next Tec, Open Practice Solutions , Cerner Works and more....

All of our clients were paid the PQRI and E-prescribe bonuses and we are ready for the ICD-10 change

Our staff has years of Attendance at AAO and ASCRS and attends all ongoing Ophthalmology billing and Practice Management continuing education classes. We are always knowledgeable and prepared for all government and commercial changes.

On staff MBA consultants

Call today to schedule a free on site consultation.

We will travel to you anytime to evaluate your AR and show you how we can dramatically increase your Revenue.

Call toll free at 1-888-PM-BILLING (1-888-762-4554)

Email: pmmedbill@aol.com

Web: www.pmmophthalmologybilling.com

24 hours: 516-830-1500

**VISIT US AT THE AAO TRADE SHOW,
 AT BOOTH NUMBER 1721**

Our Prestigious National Ophthalmology Clients reference list will be provided at your request



PM (Practice Management) Billing will keep an EYE on your Billing so you can keep an EYE on your patients.

BROKERAGE SERVICES

Thinking of retiring?

Practice Broker looking to list and broker the sale of select ophthalmology practices in the New Jersey, metro and suburban New York and southern Connecticut areas. Potential buyers, your colleagues, are pre-screened and ready to begin serious inquiry. All seller information is held in strictest confidence.

Please contact:


William Smith at A-1 Practice Brokers
845-255-4111

MARKETPLACE ADVERTISING **WORKS!**

Call **Karen Gerome**
 to place your
 Products & Services ad at
800-225-4569, ext. 2670
kgerome@advanstar.com

DIGITAL IMAGING

DOES YOUR DIGITAL IMAGING SYSTEM CAPTURE IMPRESSIVE 21MP IMAGES?



FUNDUS PHOTO DOES!

Learn more at www.itsthisgood.com 314.533.6000

EQUIPMENT

VSI
 Vision Systems Inc

New and Pre-owned

Digital Imaging Systems
 Patternless Edgers
 OCTs
 Mydriatic Fundus Cameras
 Complete Lane Packages

866.934.1030
Patternless.com

Buying and Selling
 Pre-owned Ophthalmic
 Instrumentation.
Contact Jody Myers at
(800) 336-0410 or
visit www.floridaeye.com



Repeating an ad
ENSURES it will be
 seen and remembered!

FOR SALE Nidek EC-5000 Excimer Laser
 SN50558.
 Manufacture Date 1/2000.
\$ 75,000.00
 Please Call **719.634.2001**
 for more details.

www.ophtalmologytimes.com

PRODUCTS & SERVICES

EQUIPMENT

The Leading Reseller of Premium
Preowned Diagnostic Equipment in the U.S.



800-328-2020

www.eyecarealliance.com



Repair Services
Available!

We also buy used equipment
Call 1-800-328-2020 for a quote today!

FOR SALE

Gently used Iridex IQ 810 Diode laser,
excellent condition.

Only in use for (9) months,
used (20) times, single owner.

Zeiss SL adapter, wheeled carrying
case, (4) goggles included.

Great for Retina, Peds, Glaucoma.

Sacrifice 25k or bo

Laser on West Coast, will deliver.

Respond to

diodelaser4sale@earthlink.net

Ophthalmology Times

Content Licensing for Every
Marketing Strategy

Marketing solutions fit for:

Outdoor | Direct Mail | Print Advertising
Tradeshows/POP Displays
Social Media | Radio & TV

Leverage branded content from
Ophthalmology Times to create a more powerful
and sophisticated statement about your
product, service, or company in your next
marketing campaign. Contact Wright's Media
to find out more about how we can customize
your acknowledgements and recognitions to
enhance your marketing strategies.

For information,
call Wright's Media at
877.652.5295 or
visit our website at
www.wrightsmmedia.com

PRACTICE FOR SALE

PENNSYLVANIA

PRACTICE FOR SALE

Thriving comprehensive
ophthalmology general practice in
central PA. Seller is board certified
and willing to help the purchaser
transition. This is a turnkey
opportunity available immediately
or anytime in the next year or so.

Please respond to:

eyeppractice@verizon.net

ADVERTISE **NOW!**

Combine Ophthalmology
Times Marketplace print
advertising with our online
offerings to open up
unlimited potential.

RECRUITMENT

FLORIDA

WANTED

Comprehensive Ophthalmologist,
BC/BE, Active Florida License,
full or part time, available
immediately. Salary commensurate
with experience and skills.

Contact, eyecentre101@gmail.com

CONNECT

with
qualified leads
and
career professionals

Post a job today

**Medical
Economics Careers**
www.modernmedicine.com/physician-careers

Joanna Shippoli

RECRUITMENT MARKETING ADVISOR
(800) 225-4569, ext. 2615
jshippoli@advanstar.com



Medicare fee schedule: Why it's déjà vu all over again

Proposed 24% decrease in physician payment rates not likely—if past is any indication

By Allen C. Ho, MD, *Special to Ophthalmology Times*

2014 Medicare Projected Payment Model

PROCEDURE	CPT CODE	UNITS	2013 CURRENT	2014		2013-2014 CHANGE	
				Proposed	Projected	Projected*	%*
Fundus photography	92250	CF ⁽²⁾	\$34.0230	\$25.7109	\$33.8529	-\$0.1701	-0.5%
		RVUs	2.39	2.20		-0.19	-7.9%
		\$/procedure	\$81.31	\$56.56	\$74.48	\$6.84	-8.4%

*2013-2014 calculations use 2014 projected rates, with the 2014 anticipated CF at 99.5% of the 2013 CF. (Table courtesy of Allen C. Ho, MD)

TAKE-HOME

► **Using recent history as a guide, will Medicare reduce physician payments by 24% in 2014?**

On July 8, 2013, CMS released the proposed Medicare Physician Fee Schedule (MPFS) for 2014. As currently proposed, the 2014 MPFS provides an overall decrease in physician payment rates of 24.4%.

At face value, these cuts seem drastic.

However, this should not cause immediate alarm.

Though this same scenario has played out over and over in recent years—and each year, Congress has taken action to prevent the drastic cuts—a historical review of this annual pseudo-rate cut and reprieve cycle serves as background to the forecast for 2014.

LEGACY OF SUSTAINABLE GROWTH RATE FORMULA

The sustainable growth rate (SGR)—enacted as part of the Balanced Budget Act in 1997—is a mechanism to update Medicare payment rates annually to ensure overall spending remains below a target “sustainable” level

which is tied to gross domestic product (GDP). In essence, if growth in Medicare spending exceeds growth in GDP, an automatic cut in payment rates results.

The goal of the SGR concept was admirable. However, it has not worked out as planned.

The calculated rate cuts are so unrealistic that year after year Congress has enacted special measures to block the SGR forced reductions.

To understand this annual dance, it is necessary to understand a little bit about how Medicare payment rates are calculated.

Payment amounts for each CPT code are a calculation involving two key factors:

- **The relative value units (RVUs) of the work involved in each procedure.**
- **A dollar-based conversion factor (CF).**

Each procedure paid under the MPFS is assigned an RVU based on the resources associated with that service, whereas an annual CF¹ is used to convert the RVU to a payment amount.

HISTORICAL CHANGES TO THE CONVERSION FACTOR

The proposed 2013 CF as defined by the SGR was \$24.7124. This was a 27% reduction from the 2012 CF of \$34.0376.

Late last year, Congress intervened and provided an alternate CF of \$34.0230 for all of 2013, a decrease of only 0.04%. As noted above, Congress has taken similar action in each of the past 10 years.

Last year, the action was taken before year end and applied to all of 2013, so there was no further drama.

In other years, the dance has been less smooth requiring multiple Congressional corrections for a single year.

However, the clear pattern is that Congress—often under direct pressure from physician groups—has consistently acted to prevent the drastic SGR payment cuts.

ANTICIPATED CHANGES TO CONVERSION FACTOR

The SGR proposed CF for 2014 is \$25.7109. Without congressional action, this will result in a decrease of 24.4% from the 2013 CF of \$34.0230.

Table 1 illustrates the impact of these CF changes on a common ophthalmic procedure, fundus photography. Using recent history as a guide, reimbursement experts estimate Congress will correct the 2014 CF so that it is no less than 99.5% of the current CF. That estimate is used in the 2014 Medicare Projected Payment Model in Table 1.

Continues on page 34 : Medicare

BAUSCH + LOMB

LOTEMAX[®]

loteprednol etabonate
ophthalmic gel 0.5%

Brief Summary: Based on full prescribing information.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb at 1-800-323-0000 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

INDICATIONS AND USAGE

LOTEMAX is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

DOSAGE AND ADMINISTRATION

Invert closed bottle and shake once to fill tip before instilling drops.

Apply one to two drops of LOTEMAX into the conjunctival sac of the affected eye four times daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period.

CONTRAINDICATIONS

LOTEMAX, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

WARNINGS AND PRECAUTIONS

Intraocular Pressure (IOP) Increase

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, intraocular pressure should be monitored.

Cataracts

Use of corticosteroids may result in posterior subcapsular cataract formation.

Delayed Healing

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.

Bacterial Infections

Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions of the eye, steroids may mask infection or enhance existing infection.

Viral Infections

Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal Infections

Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal cultures should be taken when appropriate.

Contact Lens Wear

Patients should not wear contact lenses during their course of therapy with LOTEMAX.

ADVERSE REACTIONS

Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with infrequent optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing and secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.

The most common adverse drug reactions reported were anterior chamber inflammation (5%), eye pain (2%), and foreign body sensation (2%).

USE IN SPECIFIC POPULATIONS

Pregnancy

Teratogenic Effects: Pregnancy Category C.

Loteprednol etabonate has been shown to be embryotoxic (delayed ossification) and teratogenic (increased incidence of meningocele, abnormal left common carotid artery, and limb flexures) when administered orally to rabbits during organogenesis at a dose of 3 mg/kg/day (35 times the maximum daily clinical dose), a dose which caused no maternal toxicity. The no-observed-effect-level (NOEL) for these effects was 0.5 mg/kg/day (6 times the maximum daily clinical dose). Oral treatment of rats during organogenesis resulted in teratogenicity (absent innominate artery at ≥ 5 mg/kg/day doses, and cleft palate and umbilical hernia at ≥ 50 mg/kg/day) and embryotoxicity (increased post-implantation losses at 100 mg/kg/day and decreased fetal body weight and skeletal ossification with ≥ 50 mg/kg/day). Treatment of rats with 0.5 mg/kg/day (6 times the maximum clinical dose) during organogenesis did not result in any reproductive toxicity. Loteprednol etabonate was maternally toxic (significantly reduced body weight gain during treatment) when administered to pregnant rats during organogenesis at doses of ≥ 5 mg/kg/day.

Oral exposure of female rats to 50 mg/kg/day of loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally toxic treatment regimen (significantly decreased body weight gain), gave rise to decreased growth and survival, and retarded development in the offspring during lactation; the NOEL for these effects was 5 mg/kg/day. Loteprednol etabonate had no effect on the duration of gestation or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the fetal period.

There are no adequate and well controlled studies in pregnant women. LOTEMAX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when LOTEMAX is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment Of Fertility

Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate. Loteprednol etabonate was not genotoxic *in vitro* in the Ames test, the mouse lymphoma tk assay, or in a chromosome aberration test in human lymphocytes, or *in vivo* in the single dose mouse micronucleus assay. Treatment of male and female rats with up to 50 mg/kg/day and 25 mg/kg/day of loteprednol etabonate, respectively, (600 and 300 times the maximum clinical dose, respectively) prior to and during mating did not impair fertility in either gender.

PATIENT COUNSELING INFORMATION

Administration

Invert closed bottle and shake once to fill tip before instilling drops.

Risk of Contamination

Patients should be advised not to allow the dropper tip to touch any surface, as this may contaminate the gel.

Contact Lens Wear

Patients should be advised not to wear contact lenses when using LOTEMAX.

Risk of Secondary Infection

If pain develops, redness, itching or inflammation becomes aggravated, the patient should be advised to consult a physician.

FOR MORE DETAILED INFORMATION, PLEASE READ THE PRESCRIBING INFORMATION.

Bausch & Lomb Incorporated

Tampa, Florida 33637 USA

US Patent No. 5,800,807

©Bausch & Lomb Incorporated

®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.

MEDICARE

(Continued from page 32)

If the proposed 2014 CF were implemented, the effect on the payment amount for CPT code 92250 would be a decrease of 30%.

However, the change in RVU for this code is a decrease of just 7.9%. As shown in Table 1, the net projected effect is small: 8% decrease in the payment amount.

Despite this positive outlook, there is still reason for concern over both the proposed 2014 CF and the broken SGR formula.

There is a high likelihood that Congress will release an updated CF prior to January 2014, drawing sighs of relief from physicians across the country.

However, it does not appear Congress will be able to resolve the larger SGR issue at this time, so it is likely that we will be rehashing this discussion again 12 months from now. ■

References

1. <http://aspe.hhs.gov/health/reports/08/sgr/sgr.html>
2. 2013 CF: \$34.0230, 2014 CF: \$25.7109 From "Estimated Sustainable Growth Rate and Conversion Factor, for Medicare Payments to Physicians in 2014." Table 5. CY 2014 Physician Fee Schedule Conversion Factor. <http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/SustainableGRatesConFact/Downloads/sgr2014p.pdf>



ALLEN C. HO, MD, is professor of ophthalmology, Thomas Jefferson University Retina Service, and serves as director of retina research and attending surgeon, Wills Eye Hospital, Philadelphia. Readers may contact him at acho@att.net. He did not indicate any proprietary interest in the subject matter.

Volunteer programs can revive physician passion

By Alison Ritchie

NEARLY EVERY PHYSICIAN WOULD agree that he or she originally pursued medicine to help others. But with changing requirements and regulations, it is easy to get caught up in the day-to-day tasks. One way to break free of that daily grind is to volunteer one's medical services, said Kate Fincham, director of program support for Health Volunteers Overseas (HVO).

"The most common comment made in our trip reports is people say, 'This trip reminded me of why I went into medicine in the first place,'" Fincham said. "That's because they're doing medicine. They're not doing insurance. They're not given only 10 minutes with a patient and told they're not allowed to take any longer than that. It does give them personal and professional fulfillment."

HVO is a non-profit organization, where medical professionals can volunteer their services across the globe. Its seven programs include a variety of subspecialties, including internal medicine, and it serves more than 25 counties in need. During a 2- to 4-week stay, HVO volunteers provide medical training and mentorship to healthcare providers in that country. Depending on the location, volunteers may be permitted to bring their spouse and their children.

Volunteers vary in their experience levels, from recent medical school graduates to physicians who have already retired from practice. For those who are just finishing up their residency, not only will volunteering look good on their curriculum vitae, it may also help them further their own training.

"It is not uncommon for doctors at that part of their training to say that they came back more confident in their skills," she said. "They have to depend on themselves and not the machines."

Physicians with an established patient base may also see professional benefits.

"If someone is traveling with us for 2 weeks to 1 month, their patients find out about this," she said. "It's an opportunity for your patients to see you in a different light."

Several organizations, such as Doctors Without Borders, are available for those who would like to volunteer with a group of medical professionals or who would like to provide immediate disaster relief.

"Physicians will look back on it and say it's one of the best things they've ever done," Fincham said.

For a list of volunteer opportunities, visit the American College of Physicians website at www.acponline.org. ■

Advertiser Index

Advertiser	Page
Alcon Laboratories Inc. Tel: 800/862-5266 Internet: www.alcon.com	7-8, 21-22, CV3
Allergan Inc. Tel: 714/246-4500 Internet: www.allergan.com	13-14
Bausch + Lomb Tel: 800/227-1427 Internet: www.bausch.com	33, CV4
Glaucoma Research Foundation Tel: 415/986-3162 Internet: www.glaucoma.org	24
Medflow Internet: www.medflow.com	15
Nicox Internet: www.nicox.com	CV2, 3
Oasis Medical Tel: 800/528-9786 Internet: www.oasismedical.com	20
Odyssey Medical Inc. Tel: 901/383-7777 Internet: www.odysseymed.com	19
Regeneron Pharmaceuticals Tel: 914/345-7400 Internet: www.regeneron.com	10A-B*
Rhein Medical Tel: 800/637-4346 Internet: www.rheinmedical.com	5
TearLab Corp. Tel: 855/832-7522 Internet: www.tearlab.com	9
TearScience Internet: www.tearscience.com	17
Wilmer Eye Institute Tel: 410/502-9634 Internet: www.hopkinscme.edu	27

This index is provided as an additional service. The publisher does not assume any liability for errors or omissions.
*Denotes regional advertisement.

OPHTHALMOLOGY TIMES (Print ISSN 0193-032X, Digital ISSN 2150-7333) is published semi-monthly (24 issues yearly) by Advanstar Communications Inc., 131 W First Street, Duluth, MN 55802-2065. Subscription rates: \$200 for one year in the United States & Possessions, Canada and Mexico; all other countries \$263 for one year. Pricing includes air-expedited service. Single copies (prepaid only): \$13 in the United States & Possessions, Canada and Mexico; \$20 all other countries. Back issues, if available are \$25 in the U.S. & Possessions; \$30 in Canada and Mexico; \$35 in all other countries. Include \$6.50 per order plus \$2 per additional copy for U.S. postage and handling. If shipping outside the U.S., include an additional \$10 per order plus \$5 per additional copy. **Periodicals postage paid** at Duluth, MN 55806 and additional mailing offices. **POSTMASTER:** Please send address changes to OPTHALMOLOGY TIMES, P.O. Box 6009, Duluth, MN 55806-6009. Canadian G.S.T. number: R-124213133RT001. Publications Mail Agreement Number 40612608. Return undeliverable Canadian addresses to: IMEX Global Solutions PO Box 25542 London, ON N6C 6B2 CANADA. Printed in the U.S.A.

©2013 Advanstar Communications Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical including by photocopy, recording, or information storage and retrieval without permission in writing from the publisher. Authorization to photocopy items for internal/educational or personal use, or the internal/educational or personal use of specific clients is granted by Advanstar Communications Inc. for libraries and other users registered with the Copyright Clearance Center, 222 Rosewood Dr. Danvers, MA 01923, 978-750-8400 fax 978-646-8700 or visit <http://www.copyright.com> online. For uses beyond those listed above, please direct your written request to Permission Dept. fax 440-756-5255 or email: mcannon@advanstar.com.

SOME SURFACES ARE WORTH PROTECTING

THE OCULAR SURFACE IS ONE.

The SYSTANE® portfolio includes products that are engineered to protect, preserve and promote a healthy ocular surface¹⁻⁵. See eye care through a new lens with our innovative portfolio of products.

References

1. Christensen MT, Blackie CA, Korb DR, et al. An evaluation of the performance of a novel lubricant eye drop. Poster D692 presented at: The Association for Research in Vision and Ophthalmology Annual Meeting; May 2-6, 2010; Fort Lauderdale, FL. 2. Davitt WF, Bloomstein M, Christensen M, et al. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation. *J Ocul Pharmacol Ther.* 2010;26(4):347-353. 3. Data on file, Alcon. 4. Wojtowica JC, et al. Pilot, Prospective, Randomized, Double-masked, Placebo-controlled Clinical Trial of an Omega-3 Supplement for Dry Eye. *Cornea* 2011;30(3) 308-314. 5. Geerling G., et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction. *IOVS* 2011;52(4).

Alcon®

a Novartis company

Systane®
Family of Products



Surface Protection and More

NOW AVAILABLE LOTEMAX® GEL

UNIQUE FORMULATION DESIGNED
TO CONTROL INFLAMMATION

FIRST IN CLASS*
GEL DROP



Indications and Usage

- LOTEMAX® GEL is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery

Important Risk Information about LOTEMAX® GEL

- LOTEMAX® GEL is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures
- Intraocular pressure (IOP) increase—Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored
- Cataracts—Use of corticosteroids may result in posterior subcapsular cataract formation
- Delayed healing—Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation and occurrence of perforations in those with diseases causing corneal and scleral thinning. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification

- Bacterial infections—Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infection. In acute purulent conditions, steroids may mask infection or enhance existing infections
- Viral infections—Use of corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and exacerbate the severity of many viral infections of the eye (including herpes simplex)
- Fungal infections—Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use
- Contact lens wear—Patients should not wear contact lenses when using LOTEMAX® GEL
- The most common ocular adverse drug reactions were anterior chamber inflammation (5%), eye pain (2%) and foreign body sensation (2%)

Please see brief summary of full prescribing information on adjacent page.

*Ophthalmic corticosteroid.

References: 1. LOTEMAX GEL Prescribing Information, September 2012. 2. Fong R, Leitritz M, Siou-Mermet R, Erb T. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. *Clin Ophthalmol*. 2012;6:1113-1124. 3. Data on file, Bausch & Lomb Incorporated.

©/™ are trademarks of Bausch & Lomb Incorporated or its affiliates. ©2012 Bausch & Lomb Incorporated. US/LGX/12/0066 [12/12]

 **LOTEMAX® GEL**
loteprednol etabonate
ophthalmic gel 0.5%
DISCOVER THE POWER OF GEL

BAUSCH + LOMB